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ABSTRACT

The components contributing to cancer progression, especially the transition from
early to invasive are unknown. Consequently, the biological reasons are unclear as to
why some patients diagnosed with atypia and ductal carcinoma in situ (DCIS) never
progress into invasive breast cancer. The “one gene at a time” approach does not
sufficiently predict progression. To elucidate the early stage progression to invasive
ductal cancer, expression signature of transcripts and transposable elements in
micropunched samples of formalin-fixed, paraffin embedded (FFPE) tissue was
conducted. A bioinformatics pipeline to analyze poor quality, short reads (>36 nts) from
RNA-Seq data was created to compare the most common tools for alignment and
differential expression. Most samples from patients prepared for RNA-seq analysis are
acquired through archived FFPE tissue collections, which have low RNA quality. The
pipeline analytics revealed that STAR alignment software outperformed others.
Furthermore, our comparison revealed both DESeq2 and edgeR, with the estimateDisp
function applied, both perform well when analyzing greater than 12 replicates.
Transcriptome analysis revealed progressive diversification into known oncogenic
pathways, a few novel biochemical pathways, in addition to antiviral and interferon
activation. Furthermore, the transposable element (TE) signature during breast cancer
progression at early stages indicated long terminal repeat (LTRs) as the most abundantly
differentially expressed TEs. LTRs belong to endogenous retroviruses (ERV), a subclass
of TEs. The retroviral and innate immune response activity in DCIS, which indirectly
xi

corroborates the increase in ERV expression in this pre-malignant stage. Finally, to
demonstrate the potential role of TEs in the transition from pre-malignant to malignant
breast cancer we used pharmacological approaches to alter global TE expression and
inhibit retrotransposition activity in control and breast cancer cell lines. It was expected
that dysregulation of TEs be associated with increased invasiveness and growth. However,
our results indicated that DNA methyltransferase inhibitor 5-Azacytidine (AZA)
consistently retarded cell migration and growth. While unexpected, these findings
corroborate recent studies that AZA may induce an interferon response in cancer via
increased ERV expression. This body of work illustrates the importance of understanding
bioinformatics methods used in RNA-seq analysis of common clinical samples. These
studies suggest the potential for TEs as biomarkers for disease progression and novel
therapeutic

approach

to

investigate

xii

in

additional

model

systems.

Chapter One:
Breast Cancer, Transposons, and Transcriptomics

1.1 Breast Cancer
Breast cancer is a disease of the breast tissue in which cells grow and proliferate
aberrantly. Ductal carcinoma is the most common type of breast cancer originating in the
ducts that transport breast milk from the lobular glands to the nipples. Some less common
breast cancers, e.g., lobular cancers, start in the glands that produce the milk () and rare
cases start in other tissues of the breast. Ductal carcinomas become invasive upon
escaping the basal membrane of the duct and invade the surrounding tissue.

1.1.1 Statistics
Breast cancer is one of the most common types of cancer in American women.
Currently, 1 in 8 women and 1 in 833 men will be diagnosed with breast cancer sometime
in their life. Approximately 20% of all breast cancers are diagnosed at pre-malignant
stages [1]. Noteworthy, only ~one-third of patients diagnosed with a pre-malignant breast
cancer will progress into an invasive form [2-4]. The American Cancer Society estimates
that 266,120 women and 2,550 men will be diagnosed with invasive breast cancer in 2018
[5]. The rate of incidence generally climbs with age. According to the CDC, in 2015 woman
between the ages of 40 and 44 had an incident rate of 126 per 100,000 women. This rate
increased and peaked in women between the ages of 70 and 74 at 462 per 100,000
1

women. While age is the most prominent risk factor for cancer, ethnicity, race, and sex
also play a role in susceptibility. For example, Caucasian and African-American women
have the highest rate of new cancers at 126 and 123 per 100,000 respectively, whereas.
Asian/Pacific Islander, Hispanic, and Native American women had rates at 94, 93, and 71
per 100,000 respectively [6].
Breast cancer is the second leading cause of death in women, behind lung cancer.
The chance a woman will die from breast cancer is 1 in 38. The earlier breast cancer is
diagnosed, the greater chance of surviving 5 years. If the cancer is at stage 0 or I the
chance of surviving 5 years is 100%. Stage II and III have a 5-year survival rate of 93%
and 72%, respectively. Stage IV breast cancer has a dramatic decrease in survival rate with
only 22% of patients surviving the next 5 years. The average survival rate for the first 5
years after diagnosis is 90% and 83% for 10 years after diagnosis [7].

1.1.2 Risk factors
A clear majority of breast cancers develop sporadically clouting its etiology.
However, there are well established risk factors associated with increasing your chances
of developing breast cancer. The most common non-genetic, non-modifiable risk factors
are age, race, early menarche, late menopause, and history of breast cancer. Non-genetic
modifiable risk factors include income, education, insurance status, reproductive
patterns, menopausal hormone use, tobacco use, alcohol use, fitness and nutrition.
Genetic risks factors include mutations in one of the two BReast CAncer (BRCA)
susceptibility genes.

2

1.1.2a Non-genetic, Non-modifiable Risk Factors
As mentioned previously there is an increase in breast cancer incidence and
mortality proportional to increasing age. Disease incidence begins to have a sharp incline
starting at age 40 and peaking at age 60 throughout the world. The median age at death
due to breast cancer is 68 years. African American women have a median age of death at
62 years while non-Hispanic Caucasian women’s median age of death is 69 [8] , which
may suggest either a genetic predisposition or health disparity by ethnicity.
Besides the significant disparity in age of death, there additional health disparities
between non-Hispanic Caucasian women and African-American women for breast cancer
statistics. In addition, African-American women have the highest 5-year breast cancer
mortality rate irrespective at stage of diagnosis, indicating that early detection is not
yielding better health outcomes. In 2012, the breast cancer death rate was 42% higher in
African-American women than in Caucasian women [9]. Even after controlling for stage
of disease, tumor characteristics, follow-up, uniform treatment, and other breast cancer
risk factors African-American women were more likely to die from breast cancer [10-12].
Furthermore, African-American women are more likely to develop a genetically more
aggressive type of cancer, having the largest proportion of HR-/HER2 breast cancer
compared to other ethnicities [9, 10]. The HR-/HER2 subtype of cancer is associated with
a poor prognosis [13, 14]. Conversely, the lowest incidence and mortality rates in the
United States of America belong to Asian/Pacific Islander women followed closely by
Alaskan natives, American Indians, and Hispanic women [9, 15]. The reason for lower
breast cancer incidence in these ethnic groups is speculated to be associated with different
reproductive patterns. Specificity, increased duration of fertility increases the risk of
developing breast cancer [16]. For example, girls who start menstruating before the age
3

of 11, have a 20% higher breast cancer risk than girls who begin at age 13. Furthermore,
women who began menopause at 55 years old had a 12% higher chance of breast cancer
compared to women who began menopause at 50-54 years old [17].
Another biological risk factor is density of breast tissue increases the risk of breast
cancer [18]. Women with breast density greater than 50% and 26%-50% were 2.3 and 1.6
times higher risk for breast cancer diagnosis compared to women with breast density
between 11%-25% [19, 20]. These observation are further convoluted because denser
breasts are harder to diagnose from impaired mammographic detection [21].
1.1.2b Nongenetic, Modifiable Risk Factors
Reproductive patterns. Women who have their first child at a younger age and
a greater number of children have a decreased breast cancer risk. Conversely, delaying
childbearing, having fewer children, decreased length of time breastfeeding, and
hormonal contraceptives are linked to increased breast cancer risk [22, 23]. There is a
50% reduced lifetime risk in women having a first child before the age of 20. There is an
association of decreased breast cancer risk when the first child is closer to menarche [5,
24]. Premenopausal breast cancer risk is increased by 5% for each year the first birth is
delayed from menarche. Furthermore, each full-term pregnancy was shown to lead to a
12% decrease in postmenopausal breast cancer risk [25]. For every year of breastfeeding
there is a 4% reduction in a woman’s risk of breast cancer.
Hormone Replacement Therapy. There is a higher risk correlated with
prolonged use of post-menopausal hormones use, from starting hormone replacement
therapy at the start of menopause, and using combined estrogen and progestin [26]. The
risk appears to dissipate back to baseline after 5 years of discontinued use of synthetic
hormones [27].
4

Tobacco Use. There is evidence that smoking prior to menopause will increase a
woman’s risk of developing breast cancer. Furthermore, women who started smoking
before their first pregnancy had a 21% higher risk of developing breast cancer. Conversely,
some studies show that women who start smoking after menopause had a decreased risk
of developing breast cancer, possibly due to an antiestrogenic effect of tobacco [28, 29].
Alcohol Use. Many studies have found a dose-dependent association of alcohol
consumption and increased breast cancer risk [30, 31]. Other studies found chronic
alcohol consumption associated with breast cancer incidence. Further studies identified
binge drinking associates with cancer incidence [32]. While the type of alcohol consumed
didn’t affect the incidence rates, the majority of breast cancers associated with alcohol
consumption are the estrogen receptor positive subtype [33-35].
Socioeconomic Status. Socioeconomic status is more complicated risk factor
for breast cancer. For example, women with higher socioeconomic status have
significantly higher rates of breast cancer incidence [36-38], whereas, the 5-year survival
rates for each stage at diagnosis are lower in patients who reside in lower socioeconomic
areas [39]. Reduced access to routine health checkups is linked to poor outcomes for
breast cancer. For instance, the group with the highest mortality rate include women
without insurance or only Medicaid [40].
1.1.2c Genetic Risk Factors
The most common hereditary breast and ovarian cancer is caused by genetic
mutations in one of the two BReast CAncer (BRCA) genes, BRCA1 and BRCA2. These
mutated genes account for 3% and 10% of all breast cancers and ovarian cancers in
women, respectively [41]. Women, without a genetic mutation common in breast cancer,
have a 12% chance of being diagnosed with breast cancer sometime in their lifetime.
5

However, women with a BRCA1/2 mutation have a 45-65% chance of being diagnosed
within their lifetime [42-44]. Men who have the BRCA2 gene mutation substantially
higher chance of a breast cancer incident. As mentioned previously, less than 1 in 1,000
men will develop breast cancer, however men with a mutation in BRCA2 have a 50-80%
in 1,000 chance of developing breast cancer [45-48]. The genetic causes of breast cancer
account for 5 to 10% of the overall breast cancer cases in women, whereas in men, up to
40% of cases are caused by a BRCA2 mutation [49]. In addition to mutations in the BRCA
genes, there is supportive evidence the following list of genes increases the risk of breast
cancer: ATM, BARD1, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, RAD51D, STK11, and
TP53.

1.1.3 Types and Subtypes
Histologically, breast cancer has been categorized, broadly, into carcinoma in situ
and invasive. Further classification of carcinoma in situ is distinguished by anatomical
location, ductal or lobular, known clinically as ductal carcinoma in situ (DCIS) and lobular
carcinoma in situ (LCIS), respectively. DCIS has been further histologically subclassified
into Comedo, Cribiform, Micropapillary, Papillary, and Solid [50]. While these
subclassifications are a valuable histological tool, these subclassifications lack molecular
definitions proven to be prognostically significant [51]. Invasive carcinomas have several
different histological subtypes, as well. The most common histological subclassification
of invasive breast cancer is infiltrating/invasive ductal carcinoma (IDC) accounting for
70% to 80% of all invasive forms [52]. IDC has been further subclassified into well (grade
1), moderately (grade 2), and poorly (grade 3) differentiated based on mitotic index,
pleomorphism, glandular formation [53]. The other major subclassifications of invasive
6

breast cancer are invasive lobular, mucinous, tubular, medullary and papillary
carcinomas.
Clinical assessments of IDC utilize molecular markers to distinguish differences in
prediction of overall survival. Traditional molecular classification of invasive breast
cancer relied on markers for estrogen receptor (ER), progesterone (PR), and human
epidermal growth factor receptor (HER2). However, through gene expression and
immunohistochemical analysis a spectrum of molecular subtypes suggests prognostic
status with five major subtypes. Claudin-low molecular subtype is typically triple negative
(ER-, PR-, HER2-), associated with the worst prognosis, and a mesenchymal phenotype
[54-56]. The basal subtype usually has a triple negative molecular profile, as well, but
mimics basal epithelial cells, similar to normal breast myoepithelial cells, with low to no
hormone receptor and HER2 expression and high basal membrane marker expression,
such as keratins and EGFR [57, 58]. The basal subtype is associated with a poor prognosis
[58, 59]. The middle of the prognostic spectrum has HER2 enriched molecular subtypes
[58, 60, 61]. HER2 overexpression tumors are typically ER and PR negative and have
enhanced expression of genes in the HER2 amplicon with a high rate of TP53 gene
mutation associations [62]. The generally poor prognosis associated with the HER2
overexpression subtype is due to the high risk of early relapse when treatment fails to
completely eliminate the cancer [61]. Luminal breast cancers have expression profiles
similar to the luminal epithelial component of the breast and are associated with ER
expression and downstream activation of ER gene pathways [57]. Luminal B tumors are
the

triple

positive

(ER,

PR,

HER2)

subtype

when

diagnosed

through

immunohistochemically, however expression profile of luminal B tumors reveal only part
of the tumors are HER2+ [63, 64]. Luminal A tumors are the ER+, PR+, and HER27

subtype and have higher expression of ER related genes but lower expression of
proliferative genes than luminal B tumors [60, 65]. In general, the luminal tumor
subtypes have a good prognosis and make up the majority of breast cancer tumor
diagnoses. However, luminal B tumors have significantly worse outcomes than luminal A
tumor subtypes [60].

1.1.4 Models of Breast Cancer
1.1.4a In Vitro
The first breast cancer cell line was derived in the late 1950s from a mammary duct
carcinoma [66]. Subsequently, breast cancer cell lines have become the principle models
for clarifying apoptosis, genetic contributors, migration, proliferation, and signaling
pathways. Currently, the most commonly used breast cancer cell line is MCF-7, which is
positive for estrogen hormone receptor expression [67]. In general, genome and RNA
sequencing has revealed the genetic and molecular expression profiles for the most
common breast cancer cell lines and revealing their shared commonalities within the
spectrum of clinical breast cancer subtypes. Briefly, no one cell line models the full
spectrum of breast cancer heterogeneity, however panels of cell lines encompass large
portions of the molecular subtyping [68-71]. Thus, breast cancer cell lines are an
appropriate experimental tool applied to derive information pertaining the specific
subtype of breast cancer resembling to its molecular profile [72]. The popularity of breast
cancer cell lines as a model of breast cancer is primarily for their ease of use and their
being perceived as more “relevant” to human disease when compared to animal models.
For example, a study showed that steroid hormone dependence is not well modelled in
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mice and the elements that contribute to transformation in mouse and human epithelial
cells are debatably different [73-76].
Furthermore, cell lines can be grown as xenografts to provide more clinically
relevant information as an in vivo model. Notably, the same cell line may adopt many
variants between labs with distinct molecular profiles and phenotypes, which may
account for variation when comparing published studies [77]. Another important
consideration about breast cancer cell lines is that a majority are grown in 2D. Twodimensional growth is different than the in vivo breast microenvironment. Recent studies
indicate that 3D culture more accurately recapitulates and expresses more pathways
found in breast [78-83].
1.1.4b In Vivo
Research using in vivo model systems has provided improved therapeutic options
for breast cancer, and observations of disease progression.
Xenografts. To investigate facets of breast cancer biology using cell lines that
more closely proximate in vivo, cell lines can be xenografted into immunocompromised
animals, such as SCID - “severe combined immunodeficiency”- strains of mice.
Furthermore, xenograft models allow investigation into multicellular interactions that
recapitulate more clinically relevant observations. These facets include tumor initiation
and growth, microenvironmental effects, and metastatic progression [84]. Albeit,
xenograft models have many limitations. First, as mentioned previously, xenografts must
be placed into immunocompromised animal models. The immune system has been
implicated in tumor progression and development for early stage breast cancer and
metastasis [85-87]. Many xenografts are generated by subcutaneous injections, which is
not a clinically relevant microenvironment. Conversely, orthotopic transplantation of
9

cells into mouse mammary glands better approximates the human patient
microenvironment. However, mouse and human mammary stroma have differences that
need to be considered [88]. Xenografts in mouse models preferentially metastasize to the
lungs and rarely grow at other common metastatic sites observed in human breast cancers
[89]. Finally, many xenografts originate from a single breast cancer cell line, which fails
to mimic the heterogeneity of intratumor. Recently, xenograft studies with entire panels
of breast tumor subtype cell lines suggest potential for a suitable translational preclinical
model in vivo [68]. Despite these limitations, xenograft models have produced many
important insights relevant to breast cancer biology, prognosis, and treatment [90-92].
Genetically engineered mice. The spontaneous tumor generation of
genetically engineered mice (GEMs) into the correct tissue of interest provides great
insight into early tumor initiating events. However, the traditional regulatory elements
used to drive transgene expression in GEMs and the mouse microenvironment may not
reflect clinical relevance. For instance, GEMs tumor pathology does not perfectly reflect
the disease in humans [93, 94]. The attempt to recreate breast cancer subtypes in vivo
has led to the generation of lineage specific promoters. To drive basal lineage oncogenic
events keratin 14-Cre and keratin 5-Cre have been used. Whey acidic protein promoter
(Wap)-Cre and keratin 8-Cre drivers target luminal cells for oncogenic events. To target
ER- or ER+ luminal cells beta-lactoglobulin-Cre and Cited1-Cre are used, respectively.
Despite these lineage specific promoters, many off-target and unexpected expression has
confounded the interpretation of experimental results [95-98]. Regardless of
confounding issues, genetic profiling of GEMs aligns to their relevant molecular cancer
subtypes [99-101].
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Furthermore, studies with GEMs representing subtypes of breast cancer has
elucidated tumor cell of origin [102, 103]. For example, the BRCA1 deficiency tumor types
was thought to originate from basal stem cells, however GEMs it delineated their cell type
of origin to luminal progenitors [104, 105].
Despite the success of targeted therapies in breast cancer, drug resistant relapse
remains an issue. Clinically relevant models of genetically engineered mice have been
generated to study drug resistance, drug combination therapies, and metastasis. These
models have elucidated putative mechanisms of drug resistance and can shutdown critical
pathways that underlie drug resistance [106-108]. The use of GEMs in preclinical breast
cancer trails for drug combination therapies relies heavily on design and collaboration
between clinicians and scientists. When considered thoughtfully such studies have
resulted in FDA approved therapeutic options [109, 110]. Although relatively few GEMs
recapitulate clinical metastases, a few GEM studies have been instrumental in elucidating
lymph and lung sites of breast cancer metastasis [111]. A recent study using CRISPR/Cas9
in combination with GEMs demonstrates their potential as a model of functional
relevance to breast cancer tumors highlighting future possibilities with GEMs [112].
1.1.4c Characteristics During Transformation
Despite these models have contributed significantly to understanding breast cancer
subtypes in late stages[113], relatively little research investigates the factors underlying
early stages of cancer transformation. There are a few hypotheses that describe the
transformation of breast cancer subtypes from normal tissue to aggressive metastasis,
which are mutation-of-origin, cell-of-origin, and a hybrid of both ideas [114-116].
Briefly, genetic profiles of subsets of normal mammary epithelial cells were derived
and compared to gene expression in breast cancer subtypes. These comparisons indicate
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there is a high overlap of normal luminal gene expression with luminal breast cancer
subtypes [117]. Furthermore, claudin-low expression profiles resembled metaplastic
CD10+, epithelial-to-mesenchymal transition, and cancer stem cell profiles [118]. These
data indicate a cell-to-lineage tumor origin. Conversely, analysis of basal-like and HER+
subtypes found expression profiles that were similar to luminal progenitor cells alluding
to a mutation-of-origin model [119, 120]. Additionally, when luminal and basal mammary
epithelial cells were isolated, transformed and implanted into immunocompromised
humanized mice, the transformed luminal cells generated both luminal-like and basallike tumors and the basal transformed cells generated rare metaplastic tumors that
resembled the claudin-low subtype [116, 121]. Currently, a hybrid model best explains
cellular transformation within the of tumor origin.
In general, metastatic ductal carcinoma begins as epithelial atypical growth inside
the breast duct surrounded by myoepithelial cells and a basement membrane. This stage
is known as early neoplasia, or more commonly as Atypia (Figure 1.1, second panel from
left). As further mutagenic events occur, a heterogeneous population arises filling the

Figure 1.1 Breast Cancer Progression Top. Histological representation of ductal breast cancer
progression. Bottom. Cartoon representation of ductal breast cancer progression. Left to right.
Normal ductal tissue, atypical growth occurs, Ductal Carcinoma in situ, and Invasive Ductal
Carcinoma. (Unpublished)
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duct, which is called as ductal carcinoma in situ (DCIS) (Figure 1.1, third panel from left).
As mentioned previously, only 1/3 of these ductal carcinomas escape the basement
membrane resulting in invasive ductal carcinoma (IDC) (Figure 1.1).
1.1.4d MCF10A & Derived Cell Lines
The numerous models available for breast cancer development and metastasis
have provided invaluable information. The MCF10A cell line is the most commonly used
model for normal breast tissue in vitro. These cells were derived from benign fibrocystic
diseased breast tissue that were spontaneous immortalized in culture. They have
amplifications of the Myc gene and genomic deletions of p16 and p14ARF genes. They are
not tumorigenic and are ER- [122]. Genomic stability studies determined that the
MCF10A cell line is fairly stable and diploid with exception to chromosome 17 which had
higher percentages of being instable [123]. When cultured on top of Matrigel they form
spheroids with a hollow lumen that is covered by a basement membrane [124, 125].
Several cell lines have been derived from MCF10A cells by inducing transformation often
with gene expression constructs. As a model of early transformation, MCF10A cells were
transformed with H-ras which generated MCF10AT cell line [126, 127]. They grow on 2D
environment, similar to the epithelial cells from which they were derived. In 3D culture
they form multi-acinar structures [128]. These cells were xenografted into
immunocompromised mice and generated nodules that progressed into atypia and then
carcinoma in situ in a quarter of the mice [126, 129]. The MCF10DCIS.com cell line was
generated from tumors that grew from the xenografted MCF10AT cell lines. Injection of
the MCF10DCIS.com cells into SCID mice produced tumors that were composed of tightly
packed tubular structures with central necrosis and basement membranes surrounding
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each node intact. Later passages of the cell line that were in injected into SCID mice
generated more aggressive and invasive tumors [130, 131].

1.2 Transposable Elements (TEs)
Transposable elements (TEs) are genetic components capable of transposing or
replicating themselves within a host genome. Barbara McClintock discovered
transposable elements through her work with maize. Initially distributing them into two
categories: TEs that are autonomously transposing, containing DNA to encode the
necessary

components

to

reverse

transcribe itself and non-autonomous TEs,
which lacks the ability to reverse transcribe
and relies parasitically upon the reverse
transcription

machinery

from

other

transposons (Figure 1.2) [132]. A widely
adopted proposed classification system for
eukaryotic transposable elements can be
found in a perspective paper [133]. There
are two classes of TEs, class I are described
as RNA mediated replication and DNA

Figure 1.2. General Classification of Transposable
Elements (TEs). (Unpublished)

mediated replication is class II. Both classes have autonomous and non-autonomous
elements (Figure 1.2).
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1.2.1 Classification of Transposable Elements in Humans
Class I TEs are often referred to as retrotransposons and include subclasses of long
terminal repeat elements (LTRs) and non-long terminal repeat elements (non-LTRs)
(Figure 1.3). LTR retrotransposons have many sub-classes; however, the most widely
known and studied are divided into the following three groups; mammalian apparent LTR
retrotransposons (MaLR), endogenous retroviruses (ERVs), and Gypsy-Ty3/Copia-Ty1
elements. The Copia/Ty1 group and the Gypsy/Ty3 group are distinguished by the
order of the three protein domains, protease (PR), reverse transcriptase (RT), and
integrase (IN), encoded within the polymerase (pol) gene of the elements.

Figure 1.3 Classification of Human Transposable Wlements. Elements are in hierarchical order
starting with generalized transposable elements moving down into classes, types, and subtypes.
(Unpublished)
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The pol region of Copia/Ty1 elements has the order (PR, IN, RT) whereas the Gypsy/Ty3
group has the more familiar arrangement (PR, RT, IN), which is also the order found in a
majority of endogenous and exogenous retroviruses.
The non-LTR retrotransposon class in humans has two sub-classes long
interspersed nuclear elements (LINEs or Ls) and short interspersed nuclear elements
(SINEs). There only two SINEs (SVA and Alu) and one LINE (L1) thought to be active in
primates from these sub-classes. L1 has an autonomous retro-transposition through an
RNA intermediate by two open reading frame proteins ORF1p, a nuclear acid chaperon,
and ORF2p, an endonuclease and reverse transcriptase [134]. L1s constitute a large
portion of the human genome, however only 80 to 100 are thought to be actively
replicating and transposing. L1 integration is initiated by ORF2p nicking the target DNA,
which serves as a primer for the local reverse transcription of ORF2p. SINEs are short
non-autonomous retrotransposons that are amplified in the genome via LINE machinery
[135]. However, they do not require the ORF1p for transposition [136]. SINE -VNTR-Alus
(SVAs) are on average ~2kbp long with a hexamer repeat region, an Alu-like region
consisting of two antisense Alu fragments, a region of variable tandem repeats, a HERVK10 env and LTR region and a poly-A signal ending with an oligo(dA) – rich tail. There
are suggestions of RNA polymerase II being the transcribing factor, however there is no
internal promoter and possibly relies on promoter activity in flanking regions [137, 138].
The Alu repeat is > 500 bps long and has a dimeric structure formed by the fusion of two
monomers from the 7SL RNA gene [139]. The 5’ region contains an internal RNA
polymerase III promoter (A and B boxes) and ends with an oligo(dA) – rich tail of
different lengths [140]. Alu’s do not possess RNA poly III termination signals and instead
extend until a terminator (usually repeat thymines) is found [141].
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Class II transposable elements are DNA transposons (Figure 1.3). These elements
are a “cut and paste” mechanism, which means they do not use an RNA intermediate like
class I transposons. Most DNA transposons encode a transposase protein flanked by
terminal inverted repeats (TIRs). The autonomous group of DNA transposons are further
subclassified into several groups, which include Tc1/Mariner [142], piggyBac [143-145],
and hATs [146, 147]. The nonautonomous DNA transposons are miniature invertedrepeat transposable elements (MITEs) [147], which do not have transposases and act as
microRNAs [148].

1.2.2 Transposition Properties & Consequences of Transposition
It has been reported that about half of the human genome is made up of repeat
elements and that the TE’s activity in the genome has been in decline [149]. The
accumulation and movement of TEs can be attributed to their selfish replicative nature
[150, 151]. Many studies have attributed TEs with influencing chromosomal structure and
rearrangement. Furthermore, TEs have been implicated in mutagenic activities.
1.2.2a Insertion Mutagenesis and Chromosomal Rearrangement
More than one hundred human inherited diseases have been causally linked to de
novo germline TE insertion mutagenesis disrupting a wildtype gene function [152, 153].
For example, a de novo transposition and insertion of Alu Ya5 SINE retrotransposon in
the ALMS1 coding sequence was found in a Turkish cohort to drive Alström Syndrome
[154]. LINEs make up the majority of these active transposition events [155]. In somatic
cells, LINE insertional mutagenesis has been implicated in tumorigenesis and malignancy
[156-158]. Additionally, TEs have been linked to several types of cancer by inducing
chromosomal rearrangements in somatic cells [159]. There is little evidence for LTR
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retrotransposons actively transposing to cause mutations in humans [74, 77, 149],
however the potential to cause mutations has not been ruled out. Conversely, in mice LTR
retrotranspositional activity inducing mutations is well documented [160, 161].
1.2.2b Insertional Site Preference and Selection
Deep sequencing technologies and classical genetic approaches have provided
detailed resolution about the integration site selection of TEs. TEs may integrate in
sequence specific locations, chromatin domains, chromosomal regions, or all along
chromosomes. Furthermore, TEs may integrate in a given preferential position but can
be subsequently selected to integrate in different specific locations.
Integration and selection preferences can vary among of mammals, including
primates and humans. In humans, L1 TEs are by far the most active but the apurinicapyrimidinic endonuclease of L1 does not appear to have a site specific preference in the
genome integrating in a dispersed manner with a bias for AT rich regions [162]. The SINE
Alu, which utilizes L1 machinery in trans for replication behave in similar manner for AT
rich site selection de novo. A majority of L1 transposition sites were rendered inactive due
to a 5’ truncation that commonly occurs during its insertion [163]. DNA transposons
encode a transposase that bind inverted repeats flanking the coding sequence of the
transposon. The transposase is responsible for excising and transposing the DNA TE to
double stranded DNA that has an identifiable short nucleotide sequence [164, 165]. LTR
retrotransposons also recognize short nucleotide sequences that usually ensure DNA
flexibility for the molecular manipulation required for integration [166-169]. Recent
studies to elucidate integration patterns of endogenous and exogenous retroviruses found
insertions were more likely to occur in gene-rich regions near active histone marks [170,
171].
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1.2.2c Recombination at TE loci
Due to the copy and paste mechanisms of many retrotransposons, they create
multiple homologous regions in the genome that can induce deletions, duplications, or
inversions of chromosomal DNA upon recombination events [172-174]. If the copy of the
retrotransposon generated is identical and in the same orientation to the first copy,
recombination may delete the sequence in between the two TEs. If the two copies are
opposite orientation, then an inversion of the sequence between them may occur due a
recombination event.

A.

B.

C.

Key
Methyl group
Reverse
Transcriptase

Integrase
New DNA locations
Figure 1.4 Long Terminal Repeat Retrotransposons Mechanisms of Regulation and
Transposition. Top 3A. DNA methylation represses LTR expression. Bottom 3A. Demethylated LTR
is actively transcribed. 3B. Reverse transcriptase from LTR turns LTR RNA into a DNA. 3C. Integrase
incorporates newly reverse transcribed LTR into novel genomic location. (Unpublished)

1.2.3 Alternative Functions of LTR Retrotransposons
Some of the observable consequences of actively transposing elements are often
interpreted by scientists that LTRs act in a selfish manner to propagate its own DNA with
potential consequence to be mutagenic. Currently, there is a lack of evidence for
retrotransposition activity in humans because generally, LTRs are heavily silenced in the
genome by DNA methylation (Figure 1.4A) and older LTRs are found greater than ~5kbps
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from native gene promoters, due to the negative impact on expression of proximal genes
[175]. Despite their quiescent transposable activity, many LTRs exhibit tissue specific
expression patterns [176-178]. For example, in mice dynamic changes in gene expression
patterns are associated with the expression of specific TEs [179-181]. Furthermore, Göke
et al. observed specific LTR families characterize the different stages of early
embryogenesis in humans [182]. Recently, it has been established that many LTRs have
been coopted for host use as promoters for coding and noncoding transcripts and ancient
viral protein expression. These alternative functions are explored further below.
1.2.3a LTRs as Alternative Promoters for Coding Transcripts
LTRs autonomously recruit cellular transcription factors (TFs) because they
contain numerous transcription factor binding sites (TFBSs) within their LTR regions.
These LTRs that contain TFBSs contribute to about 20% of functional binding sites in
humans [183]. Many LTRs have tissue specific expression and measurable transcription
levels. Interestingly, some LTRs act as promoters and drive tissue specific expression of
genes, such as (but not limited to), ADH1C in liver, CYP19A1 and ~10% of ENTPD1 in
placenta, and MKKs in testis (Figure 1.5A) [184-188]. Many LTRs generate gene variants
due to their placement in introns and can act as an alternative promoter. For example, in
~11% of melanoma cases, a LTR insertion between exon 19 and 20 of ALK acts as
alternative promoter, which generates an isoform that is constitutively active, promoting
oncogenesis [189]. Many other examples of LTRs and other TEs acting as alternative
promoters in cancer can be found here (Figure 1.5A) [190].
1.2.3b LTRs Derive Important Noncoding Transcripts
Roughly 70% of lncRNAs are associated with a TE within their transcript and
~30% of lncRNAs are derived (Figure 1.5B) directly from TEs. In a majority of genomes,
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the distribution of TEs generating lncRNAs is proportional to the percent of genomic
content they represent. Albeit in the human genome, LTRs, account for ~8% of the
genome but make up the majority of the lncRNAs derived from TEs. Conversely, LINEs
comprise ~40% of the human genome but have disproportionally low contribution in
lncRNA expression [191]. Recently, it was found that HERV-H derived lncRNAs are
highly and specifically expressed in hESCs [192, 193], define the naïve stem-cell state
[194], and are essential for the maintenance of pluripotency [195]. There is evidence that
lncRNA are not the only noncoding regions effected by TEs. For example, many
microRNAs derived from TEs have also been described as having important regulatory
roles for the host cell [196].

A.
TFBP

TE

Gene

B.
TE
Figure 1.5 Long Terminal Repeat Retrotransposons Alternative Functions. A. Alternative
promoter for downstream gene with a TFBP that has a higher affinity for the TE promoter than its
primary promoter producing high quantities of gene product. B. TE derived long noncoding RNA.
TFBP transcription factor binding protein. (Unpublished)

1.2.3c Exaptation of LTR ERV TEs as New Genes
There are a few ERVs from the LTR retrotransposon family that have had their
ancient viral genes “domesticated” for host use in placental functions, immune system
roles, and neuronal activity (Figue 1.6). An interesting example comes from the
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independently co-opted syncytin genes from ERV env regions. The products of these
genes have roles in cell-cell fusion, formation of the syncytiotrophoblast, and immune
suppression of mammal hosts during pregnancy [197-201]. Another example of a viral
particle being repurposed for host functions is the neuronal Arc gene, which is a remnant
of an ERV gag gene [202, 203]. The protein product of the Arc gene is a multifunctional
hub protein responsible for long-term synaptic plasticity which is critical for memory and
cognition [204].

E

LTR

Pol

Env

Gag

G

LTR

Figure 1.6. Long Terminal Repeat Retrotransposon Viral Protein Exaptation. Expression of
endogenous retroviral genes produce viral protein products, such as, viral envelope proteins (grey
circle labelled E) and viral structural proteins (green circle labelled G). (Unpublished)

1.2.4 Endogenous Regulation of TEs
To ensure tissue specific expression of specific TEs and minimization of negative
impacts on genome fitness TEs require tight regulation. In somatic cells, dense DNA
methylation is thought to be the main repressor of TE expression and activity [205-209].
Thus, DNA hypomethylation or demethylation occurs in these cells, TEs are de-repressed
[210-213].
Interestingly, early germline cells and the early embryo are able to control TE
expression activity without DNA methylation. These cells undergo global DNA
demethylation and yet still rely on tightly regulated repression and transcription of TEs,
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In fact the timing of the expression for specific TEs dictates the pluripotency of the cell
[179, 214]. One mechanism of specific TE repression is with Kruppel-associated box zinc
finger (KRAB-ZF) proteins whose numbers strongly correlate with the number of LTR
elements in mammals [215]. The KRAB domain is responsible for recruiting TRIM28
(also known as KAP1, Tif1β, and KRIP-1), which acts a scaffold for many proteins, such as
SETDB1 a histone methyltransferase responsible for H3K9me3 marks [216, 217]. The
major function of ~two-thirds of KRAB-ZFPs, inferred from genome-wide binding
profiles or direct loss-of-function studies, is the binding, epigenetic marking, and
repression TEs [218-221]. This suggests that KRAB-ZFPs play a major role in initiating
stable epigenetic marks via de novo methylation of ERVs throughout embryogenesis
[222]. Furthermore, ablation of the KRAB-interacting protein TRIM28 or SETDB1
activates several TEs [223, 224]. Interestingly, there is experimental evidence that some
KRAB-ZFPs function beyond early development and even control ERV expression in
adult tissues [225]. These findings suggest a tight rope regulation of sequence specific TEs
which may be necessary for tissue specific expression and activity.
Further regulation in male gametes is obtained through piwi proteins and their
associated piRNAs. Briefly, abundantly expressed TEs are spliced into pools of small
RNAs that bind to PIWI proteins and guide them to target DNA sequences. The targeted
sequences are silenced and maintained quiescent until de novo DNA methylation occurs
[226-228].
Finally, in differentiated cells, evidence of chromatin modifications associated with
condensed repressed states at TE insertions provides further regulation beyond DNA
methylation. Chromatin modifications that prevent transcription initiation at these TE
insertions are methyl marks at histone 3 lysine 9 and 27 (H3K9me and H3K27me).
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Additionally, there is a lack of transcription initiation chromatin marks at TE locations,
such as histone acetylation [229-231].

1.3 Introduction to Transcriptomics
Transcriptome analysis allows for the detection differentially expressed genes in
breast cancer vs. non-diseased tissue that may drive its pathogenesis. The variety of
technologies available to researchers makes choosing the most appropriate platform to
address and resolve specific scientific problems (or hypotheses) using transcriptome
analysis a daunting task. While some researchers believe microarrays are the most
reliable due to their maturity, others embrace next-generation sequencing (NGS) as the
superior method because it is the current vanguard of molecular technology. Assumptions
in data analysis can skew and obscure data interpretation of gene expression if the
hypothesis and, most importantly, the experimental design don’t mitigate the
shortcomings of each platform. After gene expression has been measured, the researcher
must also choose from numerous software programs and analyze expression data.
Therefore, the goal of this section is to provide brief explanations of the history, strengths,
and limitations of transcriptomics technologies as it pertains to gene expression analysis
as a resource guide to interpreting transcriptome experiments within the context of
clinical data.

1.3.1 Materials and Methods Used for Transcriptomic Studies
Transcriptome analysis creates a detailed molecular synopsis of cellular physiology
by elucidating the mRNA available for translation and/or the abundance of the various
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transcripts, such as noncoding RNAs or microRNAs. Techniques used in transcriptome
analysis belong to two broad classes; hybridization-based or sequencing-based. These two
types of transcriptome analyses are versatile to examine differential gene expression in
many cellular physiological contexts, comparing developmental stages, cell cycle, or in
disease states. The time and cost of transcriptome analysis has been greatly reduced by
the development of microarrays and, more recently, NGS, particularly when compared to
older large-scale gene expression analysis technologies such as serial analysis of gene
expression (SAGE), expressed sequence tag (EST) libraries, differential display, etc. Given
the variety of factors affecting breast cancer and the multiple pathways involved,
transcriptomics is a useful tool for diagnostics, discovery science, and pinpointing
molecular mechanisms in both clinical and translational models. Transcriptomics also
provides a way to identify and test novel treatments and therapeutics that directly correct
the underlying breast cancer, in addition to novel therapeutic approaches to alleviate
symptomology.

1.3.2 Gene Expression Analysis History of RNA Identification
1.3.2a Sanger sequencing
Sanger sequencing is the invention fundamental for developing modern methods,
such as NGS, to sequence for expressed genes in transcriptomic studies. Sanger
sequencing is the first-generation method of determining DNA nucleotide sequence based
on chain-termination idea developed in 1975. Modern modification of this classic method
is based on in vitro DNA elongation of query template, which is interrupted by occasional
incorporation into nascent DNA strands of differently labeled di-deoxynucleotide
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triphosphates (ddNTPs) present in the reaction mixture along with dNTPs. Unlike dNTP,
incorporation of a ddNTP halts extension of synthesized strand; because ddNTP is
labeled, the synthesized fragment is detected as a single band of certain color after size
separation, and collection of these bands represents DNA sequence [232]. Expressed
genes are identified using various methods to harvest RNA to make and use cDNA for
expression studies, including subtractive cloning, EST, SAGE, differential display
analysis, and microarray analysis. Once identified, gene interactions with other genes can
be pursued experimentally [232].
1.3.2b Subtractive Cloning
Subtractive cloning is an inexpensive and readily available technique in individual
biomedical and clinical laboratories to analyze gene expression using basic molecular
biology resources and bioinformatics tools. A sequence, the “tracer” is hybridized with a
complementary sequence, the “driver”, which is missing a sequence of interest. The two
sequences are combined, and reannealing is dictated by the driver, which is present at
least 10 times higher than the tracer. Once annealed, driver-tracer complexes are removed
in the subtraction step which is repeated until all common sequences are annealed and
removed. The remaining tracer sequences create a tracer specific library that represents
differentially expressed genes. Hybridization of cDNA may cause some bias for small
fragments of cDNA that hybridize faster than long sequences, but is resolved by PCR
amplification [233].
1.3.2c cDNA Libraries and Expressed Sequence Tags (EST)
In the late 1970s, cDNA libraries [234] became popular for gene discovery and
expression analysis, as the library clones were stable, reproducible, and recoverable
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representations of mRNAs isolated from distinct organs and species [235, 236]. The idea
to execute Sanger sequencing of many (i.e., >1,000) library clones to understand gene
expression in a given tissue spurred the EST project [237]. ESTs are derived from cDNA
libraries by random sampling, followed by arraying the sampled clones for future use, and
then executing a single sequencing reaction for each clone. Most expressed genes can be
unambiguously identified through these relatively short (~ 300-500 nt) EST sequences.
Data are collected using automated DNA sequencers and analyzed using bioinformatics
tools. ESTs are clustered and assembled to construct consensus sequences using, e.g.,
CAP3 program [238]. Meaningful data are generated with high throughput preparation
of either normalized or non-normalized cDNA libraries [239]. ESTs allow for de novo
gene discovery [235, 236], and large-scale prediction of gene products and function [240,
241]. An EST warehouse with high-quality data, including breast epithelium and breast
cancer, can be found in Unigene and ENSEMBL. Unigene uses reference sequences along
with Genbank mRNAs for cluster generation, and contaminants, low-complexity and
repeat sequences are identified with RepeatMasker and DUST [239].
1.3.2d Serial Analysis of Gene Expression (SAGE)
The next development in transcriptomics was Serial Analysis of Gene Expression
(SAGE) in 1995. SAGE constructs cDNA libraries in a similar fashion to ESTs but using
shorter tags to identify genes. Libraries are constructed by using restriction enzymes and
primer “linkers” ligated into the fragments encoding a recognition site for type II
restriction enzyme [242]. The cDNA fragments are then amplified and digested resulting
in the production of a 13-20 base pair cDNA fragment or “SAGE tag” and are associated
with the initial four base pair restriction enzymes. One advantage of the SAGE method is
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high-throughput sequencing resulting from its pairing with an automated sequencer
although the bioinformatics tools required to analyze the libraries are highly specialized.
SAGE analysis can be successfully used for de novo expression profiling, but the short
length of the SAGE tag can impair differentiating between highly homologous genes.
1.3.2e Differential Display Analysis
Differential Display is a PCR-based method to measure differential gene
expression. Differential Display reverse amplifies mRNA transcripts using primers from
random sequences and visualized using gel electrophoresis. The presence of a band
confirms gene expression and its intensity represents relative amount of transcript [243].
Differential display detects all expressed genes without using specific primers, making it
a robust, inexpensive discovery tool. Current advances in Differential Display incorporate
the use of fluorescent labels with automation to yield high throughput analyses [244,
245].
1.3.2f Microarray Analysis
In 1995, cDNA microarrays superseded the method of Differential Hybridization,
introducing the use of miniature spotted DNA probes and fluorescent labeling of sample,
reducing the redundancies after hybridization. Pools of known cDNAs (spot) in indexed
locations on glass slides represent known genes. Total sample mRNA is reverse
transcribed, cRNA amplified by in vitro transcription, and then hybridized to microarray
slide. The intensities of the spots produced are then recorded and analyzed by computer
software to determine the expression level of a gene [232]. One advantage of cDNA
microarrays over EST or SAGE is the ability to analyze gene expression differences under
various experimental conditions concurrently by using different fluorophores during the
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cRNA transcription. Examples of microarray technology use in breast cancer research are
X, Y, and Z. Microarray analysis requires substantially less poly(A) RNA (0.5-2.0 µg)
compared to cDNA libraries or Differential Display methods, albeit typical limitations are
the quality, specificity and signal discrepancy of the probes on the array. After
introduction, microarray analysis became commonplace and made labor-intensive cDNA
and SAGE libraries essentially obsolete, despite this method’s restriction to previously
discovered transcripts only (e.g. identified via EST libraries) and its inherent inability to
discover novel genes, alleles, or splice variants [246]. With its high throughput method
requiring low manual labor, low amount of starting RNA, and streamlined bioinformatics
processing, microarrays provide an attractive alternative to sequencing for large-scale
transcriptome analysis.

1.3.3 Next-Generation Sequencing and Deep Transcriptome Analysis
Second generation sequencing techniques emerged in 2005 and equipment
fundamentally differs from first generation sequencers because multiple different DNA
molecules are sequenced concurrently. As a result, tens of thousands to hundreds of
millions of individual sequencing reads are produced with each run. Different principles
underlying sequencing and detection and different chemistries behind various platforms
lead to large differences in read length, base call accuracy, and total number of output
reads. The largest obstacle for second generation sequencers is obtaining read length to
read quality ratios comparable to Sanger sequencing, with most platforms producing
average reads with less than 300 bases. In addition, the samples are sequenced in a stopread-start manner that leads to lengthy processing times, with some platforms requiring
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over a week for a single run to complete. To make these platforms economical, the number
of reads per run has been increased through the introduction of larger machines, such as
the Illumina HiSeq series, or denser chips, in the case of Ion Torrent. However, the larger
sequencers have a substantially higher price and require processing at full capacity to
benefit from the increased throughput and, consequently, are not typically found in
individual laboratories or small research consortia. There are smaller platforms available
from Illumina, 454 Roche, and Ion Torrent that produce longer length reads than the
larger sequencers, thereby suit the needs of small laboratories [247].
1.3.3a Basic principles of NGS sequencing
All

second-generation

sequencing

platforms

require

modification

and

amplification of sample DNA. Samples are fragmented, and adapters are annealed to the
ends. For platforms that use emulsion PCR (emPCR) to amplify the samples, the adapters
allow the fragments to bind to complementary bases on the emulsion beads. SOLiD
sequencing further modifies the fragments after amplification by adding regions that
allow the fragments to covalently bond with the sequencer slide. The Illumina platform
uses a bridge PCR to amplify the samples, which have been modified with adapters to the
base pair with oligonucleotides embedded on the sequencer slide.
Each platform also employs a different method for generating the base calls for
each sample, but only Ion Torrent does not use a light-based recording method. The base
calls are reported by pyrosequencing in 454 Roche platforms, and by fluorescent tag
cleavage in Illumina and SOLiD platforms. The Illumina platform produces forward and
reverse reads from each DNA fragment and SOLiD identifies each fragment’s bases twice,
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thereby increasing accuracy. Ion Torrent uses a microchip with pH meters incorporated
into each well to detect the release of an H+ ion with each base incorporated.
Extension of fragments occurs during sequential “flooding” of the sequencing
reaction chamber with solutions containing specific nucleotides. Illumina differs from
other platforms by using a reaction mixture containing all 4 nucleotides. The Illumina
nucleotides are modified with a fluorescent group plus a terminator to prevent
introduction of additional bases in the cycle. The fluorescence is recorded, and its tag
cleaved before flooding the sequencer with the nucleotide-containing reaction mixture
again. In pyrosequencing, the nucleotides have a modified pyrophosphate group that is
cleaved after addition. SOLiD sequencing uses di-base oligonucleotides with a 3-base
extended region and a fluorescent tag. An (n+1)-long primer is added after each round of
synthesis which, after 5 repetitions, emits two base signals for each incorporated
nucleotide. Nucleotides in Ion Torrent sequencers are added in alternating floods of A, T,
C, and G. As each base is paired to the fragment, an H+ ion is released and detected by the
sequencer microchip.
1.3.3b Development of single-cell RNA sequencing strategies
The recent ability to interrogate the transcriptome of individual cells using second
generation sequencers has revealed heterogeneity in gene expression of individual cells
within a population. As the name implies, single-cell RNA sequencing (scRNA-seq) relies
on the isolation and amplification of transcriptomes from individual cells, and many
different isolation and amplification strategies have been developed, such as Cel-seq2
[248], Smart-seq2 [249] and Drop-seq [250]. Isolation of individual cells is accomplished
by using microfluidic capture chips (Cel-seq2), fluorescence activated cell sorting (Smart31

seq2), or droplet emulsion (Drop-seq). Most scRNA-seq protocols, excluding Smart-seq,
incorporate cell-specific barcodes during the reverse transcription reaction that allows for
a large amount of multiplexing. Smart-seq, in contrast to other scRNA-seq methods,
generates full length cDNA and can more accurately differentiate between splice variants.
A side-by-side comparison of these scRNA-seq strategies found that Drop-seq was the
most cost-effective method, whereas Smart-seq was the most accurate [251]. Analyzed
cells may be clustered based on expression levels of selected genes either to detect changes
in cell populations or within a population induced by a disease.
1.3.3c Strengths & Caveats for Transcriptome Analysis
Next generation sequencers are powerful tools, but they are not without flaws and
errors that can arise at any step of the sequencing process. Firstly, errors may be
introduced by polymerase during the amplification of sample cDNA, and research
indicates this may be the primary source of errors in second generation sequencing data
[252]. Secondly, errors originate from the chemistry used by the various platforms, and
often manifest in nucleotide substitutions, insertions, or deletions [247]. The error rates
of second-generation sequencers are principally increased in homopolymeric regions
caused by incorporation of multiple bases in a single cycle. AT-enriched regions and
genomes cause increased error rates in next generation sequencers possibly from PCR
artifacts and nonrandom fragmentation of sample DNA [253]. Errors due to AT-richness
are most pronounced in the Ion Torrent platforms [254]. Furthermore, when utilizing
single-cell sequencing strategies, comparison between samples can be greatly impaired
by poor matching of samples, the stages of disease progression, and the variability
between individuals can compound the inherent heterogeneity that is present when
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comparing individual cells. While the ability to determine the response and contribution
of individual cell types to disease progression is important, more samples are necessary
to identify and distinguish between inter-individual and intra-individual variation.
For next-generation RNAseq analysis, the most important parameters to consider
in experimental design to substantially increase the quality of downstream analysis are:
the number of biological replicates, the depth of sequencing (i.e., number of reads
produced for each sample), read length, single-end vs. pair-end sequencing (i.e., each
sequenced DNA molecule is represented by a single strand read vs. two reads from each
strand), and RNA extraction. Under budgetary constraints, tradeoffs between sequencing
depth and the number of biological replicates are often made. As consistently reported,
the requisite number of biological replicates (n=3-4) is more critical for robust, reliable,
and replicable analysis than sequencing depth [255-258]. As technologies improve,
sequence lengths increase. For differential expression, little difference is seen if the length
is >25 bps, in either single-end or pair-end sequencing. However, for greater accuracy in
transcript identification and splice junction detection, reads should be pair-end and ≥100
bp [259]. The RNA extraction method impacts the ratio of RNAs present during
sequencing, and a specific strategy should be chosen with the biological or biomedical
question of interest in mind. For example, total RNA extraction is useful in capturing
unique transcriptome features, such as noncoding RNA. However, ribosomal RNA
(rRNA) comprises >90% of total RNA and should be depleted if noncoding, nonribosomal RNA is to be assessed. Current techniques cannot completely remove rRNA,
and ~2%-35% residual remains in the sample. Therefore, greater sequencing depth
should be considered when using ribosomal depletion methods to counter the abundance
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of rRNA and improve detection of other transcripts. In eukaryotic organisms, if only
protein coding genes are of interest, poly(A) selection yields greater accuracy of transcript
quantification [260]. These issues are particularly critical for clinical samples from
patients, which are routinely processed as formalin-fixed, paraffin-embedded (FFPE)
samples, which adversely impact the quality of RNA. Fortuitously, side-by-side
comparison of FFPE and flash-frozen samples shows a great degree of concordance (e.g.
r2 in the range of 0.90-0.97 in recent studies [261, 262]), proving RNAseq is a viable tool
for gene quantification in clinical settings. Controls, depending upon availability, need to
be non-diseased tissue, either of the same patient origin or from another individual
without the disease [263]. In addition, given breast cancer is a common disease, patients
are from genetically diverse, heterogeneous populations with variable symptomology,
which requires more samples to detect meaningful changes in the transcriptome truly
reflecting disease process. However, in other studies, such as breast cancer, as few as n=910 patient samples (plus samples of healthy controls), have been ample to detect specific
alleles and molecular pathways [263].
Despite the errors that may occur when using second generation sequencers,
several advantages over previous transcriptome technologies warrant their use
experimentally and clinically. First of all, second generation sequencers offer orders of
magnitude deeper coverage of sample RNA than achieved by Sanger sequencing, via EST
libraries, yielding overall faster discovery and more accurate analysis of an entire
transcriptome. Also, the length and quality of sequence produced by second generation
sequencers are much better than the fragments produced in SAGE, which improves
transcriptome accuracy. While EST typically produces fragments of at least 500bp, most
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second-generation sequencing produce shorter read lengths, albeit, read length from
second generation sequencers can be increased at the expense of read depth. Next
generation sequencers have advantages over microarrays because essentially all
expressed transcripts and their variants, can be detected, without restriction to the probes
present on the microarray chip or beads [264], plus the ability to barcode different
samples, or conditions, within a single sequencing procedure permits multiplexing of
samples.

1.3.4 Third Generation Sequencing
The latest generation of sequencers is distinguished from first and second
generations by eliminating sample amplification. Bypassing sample amplification reduces
sample preparation time and eliminates signal mismatch and distortion errors introduced
during amplification. In addition, these single-molecule sequencers produce extremely
long reads, surpassing the lengths achieved by Sanger sequencing. The Pacific Biosciences
Single Molecule Real Time (SMRT) sequencer utilizes pyrosequencing (Fig 5) in
polymerase-embedded plates, which lower the signal-to-noise ratio to detect real-time
signal processing of fluorophore cleavage. The use of pyrophosphate-labeled nucleotides
in polymerase-containing plates to extend DNA at near its natural speed facilitates
processivity and sequencing length. Another third-generation sequencing platform
available now is nanopore sequencing (MinION, Oxford Nanopore Technologies). This
technology utilizes electrophoresis of DNA molecules via nanopores (5-8 nm diameter);
as the DNA molecules squeeze through the pore, each nucleotide (A, T, G and C) produces
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a unique electromagnetic signature detected. Similar to SMRT, nanopore sequencing can
produce very long reads, up to 880 kb in a recent report [265].
1.3.4a Strengths & Caveats for Transcriptome Analysis
The Nanopore and SMRT sequencer both have ~10-15% error rate, distributed
evenly over the length of the read [265]. Fortunately, the lack of location bias in SMRT
and Nanopore reads provide sufficient coverage to extrapolate highly accurate consensus
sequences. Third generation sequencers are not yet ubiquitous, but they promise several
advantages over previous generation sequencers. The lack of sample amplification allows
for quicker, cheaper analysis and avoids the polymerase errors caused by amplification.
The long reads generated by third generation sequencers allow for more accurate
assembly of large contiguous sequences, such as whole chromosomes, complete
sequencing of whole genes in a single read [266], and identification of novel transcript
isoforms. These platforms are excellent for whole-genome and whole-transcriptome
assemblies [267, 268], including complex genomes such as gorilla [269] and human
[265]. However, at this time, third generation sequencers are at a disadvantage for use in
transcriptome analysis for quantification of expression due to the relatively low number
(e.g. ~50,000 for RSII sequencer) of output reads generated with each run comparing to,
e.g., Illumina sequencers (current typical low-end is 20,000,000+ reads per sample). The
long reads greatly improve de novo assembly and transcriptome analysis for gene isoform
identification, and the emerging technology in the field of metagenomics, which may be
important for investigating the role of microbiome imbalance in breast cancer patients.
Longer reads are also useful when assembling genomes that include large stretches of
repetitive regions. These technologies are recommended for whole genome assembly and
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splice variant detection albeit given the error rate currently not recommended for
transcript quantification.

1.3.5 Results of Transcriptome Analysis: Unbiased Data Mining
1.3.5a Differential expression analysis
In most cases, comparison of one or more conditions will result in a ranked list of
transcripts with either relative or absolute levels of expression. The typical approaches
include (1) raw data collection (processing of image files to collect intensities for
individual probes on microarrays, counts of number of reads per transcript for RNAseq
data, etc.); (2) data normalization, often followed by transformation [270]; (3) statistical
analysis to identify transcripts whose expression differences between conditions are
significant, and most importantly, (4) downstream analysis.
Microarrays of any platform are substantially more rapid to process using the
manufacturers’ software suites, such as Affymetrix’s Expression Console and
Transcriptome Analysis Console, or Illumina’s GenomeStudio. Alternative open-source,
peer-reviewed, and publicly available software for microarray analyses using the R
programming language, such as affy [271], lumi [272] and limma [273], are available as
installation packages from the Bioconductor portal [233].
For next-generation RNAseq analysis, the most important parameters to consider
in experimental design that substantially increases the quality of downstream analysis are
depth of sequencing (i.e., number of reads produced for each sample, also referred to as
“coverage”), read length, and single-end vs. paired-end sequencing. These parameters
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vary based on the goal of the biological or clinical experiment. For example, comparison
of expression between samples requires far less read depth than identification of novel
transcripts or splice variants. Journals that publish RNAseq studies sometimes also have
their own requirements for read depth. Furthermore, the length of sequencing reads
varies depending on experimental design, with longer reads typically being used in novel
transcript identification or de novo assembly generation [268]. Sequence read lengths as
low as 75 bases are sufficient for differential expression analysis [256]. Finally, pairedend sequencing from both ends of a single mRNA fragment facilitates identifying splice
variants and alignment [259].
Once the sequence is obtained from the raw signals, the quality of the output must
be assessed, based on sequence read lengths and processing direction (single-end vs.
paired-end sequencing) with either FastQC [274] or NGSQC [275]. These tools will
provide GC content, overrepresented reads, PCR artifacts, and sequence quality to detect
potential PCR bias or DNA contamination. It is usual for sequence quality to weaken at 3'
end and software programs, such as Trimmomatic [276] or FastQ trimmer [277], can
remove these low-quality 3' ends. Alignment is a critical step in RNA sequencing analysis
because raw sequence reads must be mapped precisely to an annotated reference genome
or transcriptome for the species. While it is possible to analyze RNAseq data without a
reference, e.g. by using Trinity software [278], most clinical and translational models of
breast cancer have assembled genomes available. The most common software platforms
to align RNA sequence to a reference genome are TopHat [279], HiSAT [280], and STAR
[281]. These platforms differ with respect to speed, memory usage, and their algorithms
for handling base and splice junction alignment precision, with HiSAT and STAR
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optimized to process large datasets (>108 reads), whereas TopHat is designed for smaller
datasets (<2×107 reads).
Measurement of transcript expression in RNAseq data is based on quantifying raw
counts at each genetic locus along the chromosomes using an assembled genome with
programs such as HTSeq-count [282] or featureCounts [283]. This approach uses a GFF
(Generic Feature Format) or GTF (General Transfer Format) file that contains gene
coordinates, identifiers, and descriptions in a strict predefined format [284]. All the reads
that map within the genomic coordinates of a given feature (e.g., gene, exon) contribute
to the count number of this feature. The counts from the RNAseq data are corrected for
sequencing depth and often for length of gene transcripts because smaller datasets will
have fewer count numbers, with the consequence that longer transcripts will have higher
representation among raw RNAseq reads. The majority of normalization methods report
the amount of transcript expression as reads per kilobase of exon per million reads
(RPKM), fragments per kilobase of exon per million of reads (FPKM), transcripts per
million (TPM), or counts per million (CPM) [285-287].
1.3.5b Enrichment Analysis: Overview of Biological Ontologies
Description of gene functions in scientific literature can vary significantly between
authors, even if both are describing the same phenomenon. Consequently, unbiased
grouping of genes by functional similarities may become a daunting endeavor. To
facilitate the task of describing the universe of genes, the methods of formal ontology were
applied to create the first controlled vocabulary to standardize gene descriptions across
species and disciplines. The resulting Gene Ontology (GO), and GO Consortium were
formed in 1998 to create a framework for standardizing gene products description [288].
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Since inception, GO was used to annotate millions of genes, with over 1,350,000
annotations for H. sapiens, R. norvegicus, and M. musculus genes alone. The highestlevel annotations for genes in GO are a trinity of molecular function, cellular component,
and biological process. Currently, GO uses 29,623 “Biological Process”, 11,139 “Molecular
Function”, and 4,189 “Cellular Component” terms, and strict rules to describe evidence
linking a gene to a term (from relatively vague “Inferred from Sequence or structural
Similarity” to strong “Inferred from Experiment”), to annotate genes across the tree of
life; taking into account the total number of annotated genes in species, currently average
number of annotations ranges from 5 for E. coli to 21 for R. norvegicus. GO is organized
as a graph, with individual terms being nodes, and relationships between terms being
edges. Currently, there are 8 types of relationships between terms, and the “is_a”
relationship gives this ontology a loose hierarchy, with more general terms being “parent”
to more specific “child” terms [288]. Curation remains an ongoing process, including the
field of breast cancer, and new annotations, and new GO terms are added frequently as
scientific and specific knowledge expands. The dynamic nature of GO catalyzes new
discoveries to be readily integrated into the existing ontology while older annotations are
updated with new information as it becomes available. Following the success of GO, other
ontologies began to emerge to formalize biological and biomedical knowledge to assist in
large-scale data analysis and discovery of new treatment avenues. Relevant examples
include Mammalian Phenotype Ontology [289] and Human Phenotype Ontology [290],
both used to formalize descriptions of normal and breast cancer phenotypes. Another
example, Protein Ontology, describes evolutionary relation, isoforms, and complexes of
proteins [291, 292]. These and other ontologies collectively form an Open Biological and
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Biomedical Ontology (OBO) Foundry and share common goals to facilitate curation,
management, distribution, and analysis of data [293].
Analyzing the data produced from transcriptome analysis facilitates researchers to
explore gene functions, expression levels, differential gene expression, organismal
responses to environmental and developmental changes, and more. Understanding these
characteristics can allow for the identification of highly specific drugs or disease
biomarkers. When analyzing transcriptomes of samples, the key focus is the difference of
expression levels of various groups of genes.
1.3.5c Using Ontologies & Pathway Analysis for Precision
Medicine in Breast Cancer
Precision medicine classifies individuals according to their underlying
susceptibility, prognosis, or targeting potential treatment response. Unlike DNA
sequencing focusing on genome, RNA sequencing produces the snapshot of the full
transcriptome, and has the capability to fulfill precision medicine to classify patients at
both molecular and cellular levels when used in conjunction with programs for ontologies
and pathway analysis. Development of RNA sequencing pipelines is important for
implementation of transcriptomics as precision medicine [294], which can be used
successfully to classify patient or model attributes and predict therapeutic response and
ultimate outcomes. Classifying patients based on symptoms is limited because symptoms
often arise from numerous origins or multimodal pathways, as the case with breast
cancer. Biomedical researchers in both clinical and basic research settings need to choose
transcriptome analysis to the specific characteristics of disease, and its pathology, to
detect changes in the target molecular, cellular and physiological pathways under
41

scientific scrutiny. Transcriptomics is a robust method to measure both common and
unique pathways simultaneously. For unbiased detection in molecular and cellular
pathways, researchers need to use a variety of tools, from read alignment to ontological
analysis.
The first step of ontological analysis of genes is its annotation for its biological
process, cellular component, and molecular function. Once all the gene annotations have
been collected, they are grouped by category, and these categories are analyzed for
enrichment or depletion against a “universe set” of all the genes of an organism. The
number of annotations to a distinct ontological term in a list of genes, for example, a list
of downregulated genes in invasive ductal breast cancer (IDC) vs. normal breast
epithelium is compared to the number of annotations to this term among genes in the
universe set (i.e., all genes in the genome) to identify if the occurrence of this term in the
experimental results is higher or lower than expected from a random sampling of the
universe set. This analysis facilitates discovery of common biological themes, based on
ontologies, within the lists of genes. Multiple tools exist for determining pathway
enrichment; among preferred tools in our laboratory is the VisuaL Annotation Display
(VLAD [295]), which allows to define the “universe set”, simultaneously use more than
one query set, as well as operate with any ontology within OBO Foundry, rather than only
GO.
In particular, the ability to upload own “universe set” of genes allows for more
precise identification of over- and underrepresented ontologies, while the ability to
upload any ontology from OBO Foundry allows exploration of additional ontologies such
as Mammalian Phenotype [289]. Importantly, in the online version of VLAD, GO
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annotations, as well as nomenclature of mouse and human genes are updated weekly
automatically [295] although local installment of VLAD requires the individual laboratory
to manually update gene annotations from GO. Similar tools, such as AmiGO [296],
BiNGO [297], DAVID [298], GOrilla [299], are also very popular free public resources to
identify GO term overrepresentations in the lists of genes, however, many of these
excellent tools lag behind in updating their gene annotations by as much as 3-4 years.
Similar idea of measuring and testing overrepresentation within a group of genes of
interest is implemented in Gene Set Enrichment Analysis (GSEA) [300], and commercial
platforms such as Ingenuity Pathway Analysis (IPA) [301] and Pathway studio [302].
Another useful tool to identify specific pathways in the large-scale gene expression
data is MetaCyc [303], which contains a collection of curated biochemical pathways,
annotated with organism-specific data on genes, pathways, proteins and compounds.
MetaCyc tool, Cellular Overview, allows the user to upload gene expression data and
visualize the expression upon the entire metabolic map while simultaneously retaining
the ability to focus on individual pathways affected by disease or condition, such as atypia,
DCIS, or IDC samples from breast biopsies [85]. For mammals, curated databases include
human [304], mouse [305] and cattle [306]. Differentially expressed gene lists can also
be overlaid onto existing cellular pathways using portals such as Reactome [307] or the
Kyoto Encyclopedia of Genes and Genomes (KEGG) [308] to explore potential secondary
pathways, and dysregulated pathways specific to breast cancer pathology or healthy
samples. Importantly, research community involvement in the process of gene annotation
and curation, including creation of disease-specific ontology terms, improves the
precision and quality of these resources to breast tissue and breast cancer research [309].
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1.3.6 Summary of Transcriptomics Approaches
Transcriptome analysis is a dynamic tool, whose efficacy and efficiency are
continually improving. The variety of platforms available to perform such analyses is a
great advantage to laboratories both large and small, and the high-throughputs for some
of these technologies provide rapid results with great accuracy. Identification of affected
pathways using transcriptomics bioinformatics tools allows researchers and clinicians to
make a focused and informed decision on the genes to concentrate on as potential
therapeutic targets in precision medicine. Application of transcriptomics can facilitate the
exploration of underlying pathogenic mechanisms, identification of genetic variants,
determination of treatment effects, including screening for molecular biomarkers.
Importantly, expression signatures in diseased phenotypes may pinpoint precise
interventions required to alleviate the disease state, a goal of precision medicine, without
a need for the cost prohibitive personalized assembly and deep analysis of patient’s
genome. Thus, transcriptomics can classify individuals while simultaneously facilitate
discovery, testing, and validation of new therapeutics for patients with breast cancer,
defined at the cellular and molecular levels.

1.4 Objectives, Hypotheses and Aims of Studies
Great efforts have been made to determine the etiology of human invasive breast
cancer. Currently, many studies have identified several risk factors and mutated genes
associated with breast cancer. However, the components contributing to malignancy
progression from DCIS to IDC are unknown and there is unmet need for prognostic
markers to identify patients that will develop malignancy. Interestingly, a recent study,
using spatially resolved single-cell genome sequencing, posits that in DCIS to IDC breast
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cancer, genome evolution occurs early in tumor progression and prior to invasion [310].
This study is counter to the bottleneck theory that suggests a single clone is selected for
basal membrane escape or invasion into surrounding tissue [311]. This early
heterogeneity suggests there could be additional factors involved in basement membrane
escape. It is well known that cancer genomes display a decrease in epigenetic regulatory
marks, except for in CpG rich promoter regions of tumor suppressor genes where
hypermethylation occurs. Recently, such dysregulation was described in breast cancer
progression, as well [312]. It is well known that LTR TEs, when deregulated through
demethylation, drive cell fate and potency as each pluripotent state is linked with the
activation of distinct classes of TEs [313]. We hypothesize that a change in the LTR
expression signature plays a role in the cell fate shift of breast tissue transformation to
metastasis. To test this hypothesis, we aimed to develop a bioinformatics pipeline to
accurately analyze gene and TE expression from RNA-Seq data derived from formalinfixed, paraffin-embedded (FFPE) clinical samples. Next aim is to, identify the genomewide retrotransposon expression signature during breast cancer progression. Lastly, we
aimed to demonstrate that TE expression contributes to the transition from premalignant to malignant breast cancer by altering their repression and mobile activity
through direct and indirect inhibition of DNA methylation and reverse transcriptase and
integrase inhibition.

1.5 Significance and Impact on Health
Current clinical imaging and detection technologies have increased the number of
diagnoses of very early breast cancer, including atypia (early neoplasia) and ductal
carcinoma in situ (DCIS). As previously mentioned only one-third of these early
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diagnosed breast cancer cases will progress into an invasive form. Our current
understanding lacks the capability to identify early breast cancer diagnoses that will most
likely transform into invasive carcinoma. Current treatments for individuals diagnosed at
pre-malignant stages of breast cancer involve breast conserving surgery with radiation
therapy or a mastectomy. While there are clear benefits to receiving radiation therapy
with breast-conserving surgery, there are also drawbacks [314]. For example, radiation
therapy is administered to the whole breast, requires daily treatments, and is associated
with an increased risk of secondary cancers [315, 316]. Mastectomy is the second most
likely treatment for DCIS, especially with patients who have a mass of 4-5cm or more
[317]. Patients who undergo mastectomy have a very low probability of a recurrence.
However, patients are still at an increased risk of an untreated breast developing DCIS or
IDC [318]. Some patients who elect for mastectomy have lifelong side effects that
adversely affects their quality of life, such as phantom pain, fatigue, lymphedema and
hormonal dysregulation issues. Understanding the mechanisms of breast cancer
transformation is imperative to treatment and care of the ~80,000 patients diagnosed at
early stages of breast cancer before IDC each year [319].
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Chapter Two:
Bioinformatics optimization of clinical samples

2.1 Introduction
After next-generation sequencing was introduced in 2005, many high-throughput
“next-generation” sequencing (NGS) approaches followed [1]. One of the approaches
introduced in 2008, RNA sequencing (RNA-seq), captures transcriptomes from
collections of cells or tissue samples. Reads generated by RNA-seq can then be used to
assess single nucleotide polymorphisms (SNPs), detect splice variants, detect fusion
genes, and measure individual transcript abundance in the samples for differential
expression analysis. Thusly, this exciting technology has since been used for diagnoses,
prognoses, and therapeutic selections [2-4]. In comparison to previous popular
technologies, microarrays, RNA-seq provides better transcriptome coverage and is more
suitable for discovery science, as the identification of expressed genes is not limited to the
probes present on the array [5, 6]; on the flip side, gene expression analysis becomes
computationally more challenging due to the requirement to identify each and every read
output in RNA-seq dataset. However, as NGS technologies and computers able to run the
analyses have become cheaper, RNA-seq has expanded rapidly producing massive
amounts of data to be analyzed.
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2.1.1 Research Purpose and Approach
Many everyday experimentalists and clinicians, who utilize RNA-seq in their
experiments, rely on outsourcing to cores or companies which generate and analyze their
RNA-seq data. This practice is common with many niche experiments, particularly omics
based. The purpose of the research is to bridge the gap between those in the RNA-seq
niche and the everyday experimentalist or clinician by showcasing the importance of
understanding biological conditions and the bioinformatics analysis applied.
For an ideal RNA-seq experiment, researchers and clinicians would require freshly
frozen tissue samples with minimal contamination from other tissues (e.g. blood, fat).
However, most clinical research relies on archived tissue samples (formalin fixed paraffin
embedded, FFPE), or are hindered by limited sample material from biopsy collection. It
is worth noting that FFPE samples have increased nucleotide degradation and decreased
poly(A) binding affinity [7-9]. We analyze RNA-seq data from formalin fixed paraffin
embedded tissue, which is highly variable for quality and depth of reads. We believe the
quality and depth of these data to represent the quality and depth of data the everyday
researcher or clinician will likely work with. One of the most common biological question
asked when analyzing RNA-seq data is, “What genes have different levels of transcription
in one experimental condition when compared to another experimental condition?” To
determine differential expression, RNA-seq reads need to be assessed for quality and then
aligned to a reference genome.
After quality control checks, alignment is most often the first step in RNA-seq
analysis and any analysis thereafter relies heavily upon this initial step. Generally, when
available and well annotated, reads obtained from sequencing will be mapped to either a
reference genome or a transcriptome of a species. For simplicity, we will be describing
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tools and settings for mapping to a reference genome. For in-depth discussion, see a
recent review by Conesa et al [10]. The biggest challenge for aligning RNA-seq reads to a
reference genome is that most reads have exon-exon splice junctions. The most common
software platforms available for mapping to a reference genome, TopHat [11], HISAT2
[12], and STAR [13], identify splice junctions. Where these platforms differ is
computationally, with respect to speed and memory usage, and their algorithms for
handling base and splice junction alignment precision. TopHat is currently not
maintained and has been superseded by HISAT2 due to computational inefficiencies,
both of which are built on the short read mapping program Bowtie2 [14]. While all three
aligners are considered fast, HISAT2 and STAR consistently outperform TopHat with
respect to computational speed [13, 15, 16]. Baruzzo et al [16] and Engstrom et al [17],
provide insight into the major differences in aligner performance. All three aligners
performed well in placing a read onto the respective genomic locus. However, significant
discrepancies and deficiencies were found for TopHat in getting a read to align or total
percent mapped. Here we evaluate the alignment performance of STAR and HISAT2 due
to the discrepancies in TopHat performance in previous comparison papers.
The relative expression level of genes is estimated based on the number of mapped
reads. These counts are subjected to statistical tools to assess significant differences
between groups. Here we explain and assess the strengths and weaknesses of the two most
widely used differential expression analysis tools, DESeq2 [18] and edgeR [19]. A
simplified bioinformatics pipeline for raw data to differential expression analysis can be
found in Figure 2.1. We performed differential gene expression analysis using the series
of breast cancer progression RNA-seq data from FFPE samples. In our comparison we
assessed similarities and differences in the results, to test if (and how) different aligners
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affect the gene expression level counts or location of mapping, and if different algorithms
used for assessing differential gene expression affect the “final list” of statistically
significant transcripts, as well as downstream analysis for Gene Ontology [20]
enrichment. We focused on two of the most popular aligners, HISAT2 and STAR, and two
differential gene expression testing tools, DESeq2 and edgeR, all available for users via
the Galaxy platform, a portal designed to fulfill the bioinformatics needs of researchers
with very modest bioinformatics and programming experience.

2.2 Methods
2.2.1 Breast cancer samples
A dataset of 72 RNA sequencing experiments is deposited in NCBI SRA database
(project number PRJNA205694 [21]). Datasets represent transcriptomes of biopsies from
different stages of breast cancer: 24 normal tissues, 25 early neoplasia (EN), 9 ductal
carcinoma in situ (DCIS) and 14 infiltrating ductal carcinoma (IDC), from 25 patients.
Briefly, RNA was extracted from core punches of FFPE specimens after histological
confirmation of the cancer stage; only samples that possessed >90% of luminal cells with

Figure 2.1. Bioinformatics pipeline for RNA-Seq tool analysis (Unpublished)
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the appropriate diagnosis were used. Directional cDNA libraries were constructed and
sequenced using Illumina GAIIx to obtain 36-base single-end reads. We used these data
to compare two common aligners, STAR and HISAT2, and differential expression tools,
DESeq2 and edgeR (Figure 2.1).

2.2.2 RNAseq reads alignment
We used two different programs, STAR and HISAT2, to align the RNAseq reads to
the reference human genome assembly (hg19). For more precise alignment, both
programs use a dataset of known splice sites for correct identification of potentially
spliced reads in RNAseq data; this dataset, in “gene transfer format” (gtf), was obtained
from ENSEMBL (release 87, 12/8/2016).
2.2.2a STAR
STAR’s algorithm [13] uses a two-step approach. STAR aligns the first portion, or
seed, of a read to a reference genome up to the maximum mappable length (MML) of the
read then aligns the left-over portion, second seed, of the read, up to its MML. After the
read is completely aligned, STAR stitches the two, or more, seeds together and scores
them based off a user-defined penalty for mismatches, insertions, and deletions. The
“stitched” seeds with the highest score are chosen as the correct alignment of a read. This
approach allows for quick and easy annotation of multi-mapping reads with their own
alignment scores. --seedSearchStartLmax 50 –seedSearchStartLmaxOverLread 1.0 –
seedSearchLmax

0

–seedMultimapNmax

10000

–seedPerReadMax

1000

–

seedPerWindowMax 50 –seedNonoLociPerWindow 10 –alignIntronMin 21 –
alignIntronMax

0

–alignMatesGapMax
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0

–alignSJoverhangMin

5

–

alignSJDBoverhangmin

3

–alignSpliceMateMapLmin

0

–

alignSplicedMateMapeLminOverLmate 0.66 –alignWindowsPerReadNmax 10000 –
alignTranscriptsPerWindowNmax 100 –alignTranscriptsPerReadNmax 10000 –
alignEndsType Local
2.2.2b HiSAT2
HISAT2 uses the Bowtie2 [14] algorithm to construct and search a FerraginaManzini (FM) index [22]. However, HISAT2 employs two types of indexes for aligning: a
whole-genome FM index to anchor alignments, and numerous overlapping local FM
indexes for extension of the alignment. --mp MX=6, MN=2 –sp MX=2,MN=1 –np 1 –rdg
5,3 –rfg 5,3 –score-min L,0,-0.2 –pen-cansplice 0 –pen-noncansplice 12 –pencanintronlen G,-8,1 –pen-noncanintronlen G,-8,1 –min-intronlen 20 –max-intronlen
500000

2.2.3 Gene expression counts
The simplest method for estimating transcript expression is to count the raw reads
for each annotated genomic locus in the genome assembly. This approach uses a gene
transfer format (GTF) file that contains coordinates (i.e., positions in the genome for each
exon, transcription start site, transcription termination site, etc.) and nomenclatures of
genes. We used FeatureCounts [23], a program that extracts information from bam files
for reads overlapping with features in an input gtf file containing exon coordinates for all
transcripts in the genome assembly, with the following parameters: --t ‘exon’ –g ‘gene_id’
–M –fraction –Q 12 –minOverlap 30.
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2.2.4 Data normalization and quality control
2.2.4a Data normalization
There is much confusion in the literature when reporting units of expression for
RNA-seq data. The confusion stems from the different forms of normalization required
for within sample comparison vs between samples comparison. Many methods for within
sample comparison attempt to correct for sequencing depth and gene length. These
methods produced the most frequently reported unit of expressions for RNA-seq data,
which are read per kilobase of exon per million reads (RPKM), fragments per kilobase of
exon per million of reads (FPKM), and transcripts per million (TPM)[24]. The order in
which RPKM and FPKM normalize the read counts causes differences within samples that
should not be ignored. Instead, when comparing within samples one should use TPM
values which eliminates the invariance within samples[24]. A relationship between
RPKM/FPKM and TPM is derived here[25]. Alternative normalization methods, which
allow for comparisons between samples or differential expression analysis, are available
and explained in the next section. We used CPM normalization of gene count data for
quality control step using the following formula:
CPMi = Ri / TRa × 1,000,000

where CPMi is a CPM value of a gene in a biological replicate; Ri is the number of reads
mapping to all exons of this gene in this biological replicate; TRa is the total number of
reads aligned (anywhere in the genome) from this biological replicate (i.e., the number
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of aligned reads in either STAR or HISAT2 output “binary alignment map” bam files).
This procedure also transforms data from counts to a continuous scale.
2.2.4b Quality control
For quality control, we used ClustVis [26], a statistical tool for clustering of
complex data such as RNAseq, based on principal component analysis and visualization
of results. Any samples that fell outside of the initial 95% confidence interval on the twodimensional PCA plot were flagged as outliers and removed before further analysis.
ClustVis is an intuitive user interface built on several R packages that provides Principal
Component Analysis (PCA) and heatmap plots of high-dimensional data from a data
matrix. Data may be uploaded by a delimited file or copy and pasted into the ClustVis text
box. Dimensions (e.g. genes) and observations (e.g. samples) may have multiple
annotations that can be detected automatically or input manually to provide additional
depth to the PCA and heatmap plots [26].

2.2.5 Differential gene expression analysis
According to citation reports, edgeR and DESeq2 are the leading tools for
differential gene expression analysis of RNAseq data (9,411 and 7,318 citations in Google
Scholar, respectively; retrieved 12/2018). Both tools are R packages and require raw read
counts in a data matrix which they normalize to account for differences in sequencing
depth and low count variability. Both tools assume the data will have variance beyond
what is expected in random sampling, what’s known as overdispersion. Therefore, they
assume the data will fit a negative binomial distribution and further attempt to shrink the

70

raw counts into this distribution through unique Empirical Bayes methods. To display
differential expression outputs uniformly we used the R package ViDGER [27].
2.2.5a DESeq2
DESeq2 normalizes each gene using a generalized linear model [28]. Then,
DESeq2 uses an Empirical Bayes shrinkage to detect and correct for dispersion. Unlike
early versions of edgeR, DESeq2 also uses an Empirical Bayes shrinkage on log 2-fold
change estimates. Within R, the “raw count data” was imported as a matrix along with a
“DataFrame” that has a column which annotates the columns of the imported matrix. A
DESeqDataSet was generated with these imported files using the DESEq2 function
DESeqDataSetFromMatrix(countData=”raw

count

data”,

colData=”DataFrame”,

design=~0 + Stage). The names in the quotation marks are arbitrary and assigned by the
user when importing the corresponding files all quotation marks should be removed when
using the functions in R. The design argument within the function is a formula which
expresses how the counts for each gene depend on the variables in colData. Here, the
design formula of ~0 + Stage will build a results table and plot all experimental group
comparisons. The data was filtered to keep only genes that had at least 4 counts between
at

least

10

samples

generating

the

function

keep

<-

rowSums(counts(“name_DESEQDataSetFromMatrix”)>4) >=10 and applying it to
“name_DESEQDataSetFromMatrix”

with

name_DESEQDataSetFromMatrix[keep,].

name_DESEQDataSetFromMatrix
The

DESeq(“name_DESEQDataSetFromMatrix”).
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DE

analysis

was

called

<using

2.2.5b EdgeR
EdgeR’s default method of normalization is called trimmed mean of M-values, or
TMM, obtained with the function calcNormFactors. This method of normalization
estimates the ratio of RNA production through a weighted trimmed mean of the log
expression ratios. There are alternative normalization methods available in edgeR to
account for data that does not fit the negative binomial distribution assumed with TMM.
To control for false discovery rate (FDR) we applied the estimateDisp function.

2.2.6 Gene enrichment analysis using Visual Annotation Display
(VLAD)
VLAD [29], accessible via MGI web portal, is a powerful tool to find common
functional

themes

in

the

lists

of

genes

by

analyzing

statistical

over-

or

underrepresentation of ontological annotations. Currently, users can choose among Gene
Ontology (GO) [20] annotations for human genes, Gene Ontology and Mammalian
Phenotype Ontology (MP) [30] annotations for mouse genes, or upload a file of own
annotations (in open biomedical ontology [31] ‘obo’ format). Unlike other packages for
ontological enrichment, VLAD allows analysis of more than one query (i.e., several lists
of genes may be analyzed and visualized simultaneously), as well as permits user to
provide own “universe set”, i.e. gene list to test queries. For GO analysis, we searched for
overrepresentation among terms with experimental evidence (i.e., codes EXP, “Inferred
from experiment”; IDA, “Inferred from direct assay”; IMP, “Inferred from mutant
phenotype”; TAS, “Traceable author statement”).
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2.3 Results
2.3.1 Output of aligners
All reads for all samples were aligned
to the human genome assembly (hg19).
Overall, STAR significantly outperformed
HISAT2 in aligning the FASTQ reads to the
genome (Figure 2.2). The generally low
proportion of aligned reads to all input reads
for both programs is likely due to the quality
of the libraries, as a significant number of

Figure 2.2. Performance of HISAT2 and STAR
aligners on the breast cancer series data.
(Unpublished)

input reads were poly(A) sequences, Illumina adapter sequences, and reads
corresponding to the very 3’-ends of mRNAs, which are too uninformative for correct
mapping

2.3.2 Quality control
To eliminate sample outlier biases,
we

performed

Principal

Component

Analysis of gene expression counts for each
sample by each stage for both aligners. Gene
expression counts were collected using
featureCounts and normalized to the total
number of aligned reads for each sample, and
PCA completed on these data using ClustVis
(large edition). For all subsequent analysis,
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Figure 2.3. PCA visualization of gene expression
data from HISAT2 and STAR alignments. A, B:
Clustering of HISAT2 samples on the first two principal
components before (A) and after (B) outlier removal. C,
D: Clustering of STAR data before (C) and after (D)
outlier removal. (Unpublished)

any samples that fell outside the 95% confidence ellipse in their respective stages
(Normal, Atypia, DCIS and IDC) were removed. For both HISAT2 and STAR, the same
samples fell outside of the 95% confidence ellipse in each stage (Figure 3). In total, we
identified six outlier samples in the RNAseq dataset, which were: SRX286949 (normal
tissue), SRX286945 and SRX286964 (atypia), SRX286961 (DCIS) and SRX286951
(IDC). Interestingly, the PCA plots for all stages in HISAT2 data had the Atypia stage
cluster well removed from other stages (Figure 2.3A & B). Overall, Atypia stage presented
more heterogeneity than any other stage, irrespective of the aligner.

2.3.3 Gene expression profiling
2.3.3a Highly expressed genes
To determine how concordant the alignment tools were in mapping the reads to
the genome, we compared the highest expressed genes that correspond to 50% of all reads
mapped to exons. In the normal samples, 50% of the mapped reads came from 330 and
305 genes for STAR and HISAT2 respectively and they shared 263 of those genes (Figure
2.4). In atypia samples, 50% of the mapped reads came from 417 and 406 genes for STAR
and HISAT2 respectively and they shared 40 of those genes. In DCIS samples, 50% of the
exon-mapped reads came from 469 and 416 genes for STAR and HISAT2, respectively; of

Figure 2.4. Overlap between the highest expressed genes in the RNAseq breast cancer datasets aligned
by HISAT2 or STAR. HISAT2-identified genes are in red; STAR genes are in green; overlapping genes are in
yellow. (Unpublished)
74

those, 383 genes were shared. In IDC samples, 50% of the exon-mapped reads came from
384 and 366 genes for STAR and HISAT2, respectively, and the lists shared 319 of those
genes. The high amount of discrepancies in atypia convinced us to look further into what
were the major differences in alignment.
2.3.3b Alignment to pseudogenes.
Retrogenes

are

intronless

gene

copies produced by reverse transcription of
a “parent” gene mRNA and insertion of the
cDNA copy elsewhere in the genome.
Retrogenes are often non-functional and are
generally assigned to the category of
“pseudogenes”, i.e. genomic loci harboring
similarity to a protein-coding gene but not
having

any

recognized

function.

The

sequence similarity among retrogenes and
their parent genes poses a problem for
aligners, whose algorithms must decide
when assigning a read to a specific locus in the
genome. To determine what the differences in

Figure 2.5. Expression of retrogenes in HISAT2
and STAR alignment data. A: Proportions of all
reads, by stage, aligned to annotated pseudogene
loci by HISAT2 (red) and STAR (green). B: Number
of retrogenes among highest-expressed genes by
stage, and aligner. (Unpublished)

alignments were, we analyzed the numbers of
reads mapped to pseudogenes by HISAT2, and STAR. Between two aligners tested,
HISAT2 consistently had significantly higher amounts of reads aligned to pseudogenes
when compared to STAR (Figure 2.5A). Furthermore, for Atypia stage, HISAT2 had
drastically higher amounts of reads aligned to pseudogenes than the other stages. To
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determine what portion of the top 50% of mapped reads were pseudogenes, we obtained
a list of pseudogenes from the hg19 gtf annotation file we used and compared this list with
the top 50% of mapped genes for each stage and each aligner. A single pseudogene was in
the gene list for each stage which represented the top 50% of mapped reads for STAR.
Conversely, HISAT2 consistently had higher amounts of pseudogenes represented in the
top 50% of mapped reads (Figure 2.5B).

2.3.4 Differential gene expression analysis
The differential expression comparison on data from different alignment tools was
done to further explore the consequences of previously described alignment tool biases,
as well as to compare the two popular tools used for the purpose of identification and
quantification of gene expression differences between different conditions, edgeR and
DESeq2.
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A

B

Figure 2.6. MA plots of pairwise comparisons of all stages. A. edgeR. HISAT2 (top) and STAR (bottom). B.
DESeq2. HISAT2 (top) and STAR (bottom) gene counts for all samples were analyzed to identify differentially
expressed genes. Each gene is represented by a single dot. Blue dots represent genes whose expression
difference between conditions is both significant and at least two-fold. Green dots represent genes whose
expression difference between conditions is significant, but less than two-fold; grey dots represent genes whose
expression differences between conditions is not statistically significant. Y-axis (all plots): log2 of expression fold
change; X-axis (all plots): log of gene expression mean value. (Unpublished)
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2.3.4a edgeR of HISAT2 and STAR bams
Overall patterns of differential gene
expression performed by edgeR on HISAT2
and STAR data were similar for all pairwise
stage comparisons, except atypia vs any
other

stage

consistently

(Figure
had

2.6).

the

HISAT2

atypia

stage

comparisons produce > 15,000 statistically
significant

differentially

expressed

transcripts with a log2 fold change (LFC) ≥ 1
(i.e.,

difference

in

expression

between

Figure 2.7. Numbers of differentially expressed
genes in pairwise comparisons, by aligner (HISAT2
or STAR), and quantification program (edgeR or
DESeq2). (Unpublished)

condition is at least two-fold) (Figure 2.7). Conversely, differential expression pairwise
comparisons with STAR atypia stage vs each other stage identified 350 to 2,496
differentially expressed genes (Figure 2.7).
2.3.4b DESeq2 of HISAT2 and STAR bams
Differential expression analysis using DESeq2 on pairwise comparisons of STAR
alignments Normal vs Atypia revealed 255 transcripts having LFC > 1 and 177 transcripts
with LFC < 1. Normal vs DCIS and Normal vs IDC analysis revealed 1,677 LFC > 1, 482
LFC < 1, and 2,304 LFC > 1, 1,417 LFC <1 DE transcripts, respectively (Figure 2.6B,
bottom panels). Similarly, to edgeR differential expression analysis of HISAT2 with
DESeq2 consistently produced high numbers of DE transcripts in atypia pairwise
comparisons, > 19,000 transcripts with LFC > 1 (Figure 2.6B, top panels). Normal vs
Atypia, Normal vs DCIS, and Normal vs IDC analysis revealed 19,419 LFC > 1, 1,212 LFC
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< 1, 1,585 LFC > 1, 190 LFC < 1, and 2,196 LFC > 1, 732 LFC < 1 DE transcripts,
respectively.
2.3.4c Comparison of DESeq2 and edgeR results
To compare how similar the most common differential tools, edgeR and DESeq2,
are on the same aligners we produced Venn diagrams of all DE genes each produced, for
each pairwise cancer stage comparison to normal samples. DESeq2 and edgeR shared
341, 1,678, and 2,809 of the differentially expressed transcripts on the STAR alignment
pairwise comparisons for Normal vs Atypia, Normal vs DCIS, and Normal IDC,
respectively (Figure 2.8). DESeq2 and edgeR shared 14,220, 1,433, and 2,137 of the
differentially expressed genes on the HISAT2 alignment pairwise comparisons for
Normal vs Atypia, Normal vs DCIS, and Normal vs IDC, respectively.

Figure 2.8. Overlap of genes identified as differentially expressed. Top row is HISAT2-aligned data. Bottom
row is STAR-aligned data. (Unpublished)
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2.4 Discussion
STAR had the highest average rates of mapped reads for each stage. Conversely,
HISAT2 not only had lower rates of alignment but also had increased rates of pseudogene
alignment which may have compromised alignment fidelity. We recommend STAR
alignment over this version of HISAT2. It’s important to note that no alignment tool is
right for every job and that alignment parameters play a large role in alignment outcomes.
For in depth explanations and comparisons of aligners we refer the reader to [16, 17].
Next-generation technology has improved greatly in a short amount of time.
Initially, read lengths being generated were between 25 – 36 nucleotides. Currently,
nucleotide reads can be generated at a length of >300 nucleotides. Chhanawala et al [32]
reported reads with a length of >25 nucleotides had negligible differences with differential
expression detection. Conversely to what was previously reported, we believe the short
nucleotide sequences (36nts) may have been an issue for the FM index generation utilized
by this version of HISAT2 with the annotated settings, thus propagating misalignments
to pseudogenes. However, further testing needs to be done to verify. To improve
concordance between aligners we recommend ensuring greater read lengths during
experimental design to increase alignment accuracy.
Recently, Schurch et al [33] compared the performance and accuracy of the top 11
differential tools available for RNA-Seq analysis. DESeq2 and edgeR out performed other
tools with the lowest FDR and highest true discovery rate (TDR). Further, they report
DESeq2 slightly outperformed edgeR with respect to FDR when there were more than 12
biological replicates. Here, we report DESeq2 having a higher number of significantly
differentially expressed genes. This may be counter to earlier reports of edgeR’s
propensity to a higher FDR at higher number of biological replicates. The addition of the
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estimateDisp function may have applied heavier weighted likelihood empirical Bayes
methods to obtain the posterior dispersion estimates [34]. Therefore, when dealing with
higher number of replicates we recommend using DESeq2 or edgeR with the
estimateDisp function to control FDR. When dealing with lower than 12 replicates we
believe edgeR and DESeq2 are both viable options however we recommend edgeR as it
may have an edge in false negative rates (FNR), or TDR.
These data clearly demonstrate the need for careful considerations and purposeful
intent when generating and utilizing a bioinformatics pipeline to assess differential
expression of clinically applicable RNA seq runs. Due to the increase use of RNA seq to
diagnose, prognose, and generate therapeutic options we feel that clinicians and everyday
experimentalists should have a strong foundation and understanding of the
bioinformatics tools being utilized to generate and analyze their data. This study
highlights possible limitations of this version of HISAT2 for older RNA seq read
generation technologies, poor quality sample reads, and short RNA seq reads. Thus,
providing clinicians with insights into the “right” tool for the job.
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Chapter Three:
TE & Transcript Analysis of Clinical Samples & in vitro Cell Line Model

3.1 Introduction
Etiology of breast cancer includes two major, independent, cellular decisions:
establishment of a small population of atypical cells in healthy tissue and malignant
transformation of ductal carcinoma in situ (DCIS) stage cells into invasive breast
carcinoma [1]. The pathways and the regulators underlying these cellular decisions are
currently poorly understood but clearly have genetic, environmental, and age-dependent
components. Importantly, neither of these cellular decisions is definitive because not all
healthy breast tissues will develop atypia, nor all DCIS will become deadly breast cancer
[2-4]. Detection of breast cancer at early, pre-invasive stages greatly increases the odds
for long-term survival. Early diagnosis of breast cancer often results in unnecessary
treatment for the majority of women. In fact, a recent prospective study revealed only 530% of cases of atypia will develop aggressive, invasive forms of breast cancer, whereas
the majority, 75%-95% will not [5]. The absence of diagnostic biomarkers predicting
invasive ductal carcinoma (IDC) leads to costly, unnecessary treatment [6].
There is little understanding why some patients diagnosed with atypia and DCIS
remain cancer-free for years, while in others the disease progresses rapidly to malignant
invasive ductal carcinoma. A ‘one gene at a time’ approach does not sufficiently predict
whether an early lesion will become invasive because it is based on genetic markers
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associated with developed tumors. For instance, poor prognosis for human breast cancer
strongly associates with expression and/or mutations in ERα, ERβ, HER2, PR, EGFR,
BRCA1, BRCA2 and several other genes in malignant IDC. In contrast, the genetic players
of atypia and DCIS, and their prognostic value, remain unknown. Therefore, considerable
interest lies among clinical and biomedical research community to identify the gene
expression changes driving cell fate decisions at the atypia and DCIS stages, which
ultimately skew the balance to malignant transformation.
Changes in cell phenotype from normal to atypical to malignant are reflected in
changes of gene expression, also known as “gene expression signatures”. Large-scale
studies using microarray and more recently, next-generation sequencing technologies are
proving useful in defining gene expression signatures of breast cancer progression from
early atypia to invasive ductal carcinoma. Over the last decade, a large number of
microarray gene expression studies were conducted to uncover the gene expression
signature of atypia and DCIS in human patients, mouse models of breast cancer, and
mouse-human comparisons [7-12]. Cross-comparison of microarray studies performed
by different research teams often yield little to no overlap [13], leaving the gene expression
signature of atypia and DCIS elusive. Thus, a fundamental goal of translational
bioinformatics is identification of early stage expression changes for impending invasive
breast cancer from biopsies of premalignant atypia and DCIS compared to control (noncancerous).
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3.1.1 Determining Transposable Element Expression During Breast
Cancer Progression
The role of dysregulated LTR retrotransposons as mutagenic agents is widely
known, as accumulation of retrotransposition-induced mutations in critical genes
contributes to oncogenesis [14]. Retrotransposition is a hallmark of advanced cancer
driving genome instability [15, 16]. Of note, HERV-K elements have been detected in the
plasma of people diagnosed with invasive breast cancer [17]. However, it is unknown if
specific LTR retrotransposons are expressed in the early stages of atypia and DCIS. TEs,
notably LTRs, expression at early stages indicate the mechanisms driving genomic
instability in cancer become active quite early in mammary tumor progression. Moreover,
TE expression is linked to the undifferentiated state of the chromatin from stem cell
studies, which has been implicated as a driver in cellular transformation and oncogenesis.

3.1.2 Research Purpose and Approach
The purpose of this research is to investigate, using in silico methods, the
expression signature of transposable elements during breast cancer progression. We
hypothesize that transcriptional re-activation of endogenous retrotransposons occurs
during transformation of atypia and DCIS. To test this hypothesis, we designed a
Transposon Enrichment Set Analyses (TESA) based on open-source, published tools
freely available to the scientific and research community. Furthermore, we also measured
transcript expression from transcriptome data to detect and corroborate known
oncogenic pathways.
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3.2 Methods
3.2.1 Transcript & TESA Pipeline
Classic bioinformatic pipelines generated to analyze RNA expression rely on a
reference genome file (.gtf) during the alignment process and a gene annotation file (.gtf
or .fasta), which specifies the name of the gene for the genomic location from read
alignment. Here, we generated a unique transposable element annotation file from the
RepeatMasker program [18]. The RepeatMasker screens DNA sequences for repeats and
low complexity DNA sequences then outputs a detailed annotation from the query. The
annotation file generated from RepeatMasker was then used in a RNA-Seq bioinformatics
pipeline further explained below (figure 3.1).
Briefly, RNA-Seq data of biopsies from formalin-fixed, paraffin-embedded breast
tissue during oncogenic progression were obtained from NCBI’s national database GEO
DataSets [19]. These datasets were aligned using STAR aligner to human reference file
hg19. Read summarization of transposable element counts were generated using
featureCounts [20] with the alignment file generated with RepeatMasker, as mentioned

Figure 3.1 Transposon Enrichment Set Analyses (TESA) pipeline/workflow. Orange boxes are
bioinformatic tools. Light blue boxes are output files. Dark blue boxes are input files. (Unpublished)
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previously, and transcript counts were generated using an annotation file from
ENSEMBL. To assess intrasample and intergroup quality raw counts were normalized
using counts per million, as previously described (Chapter 2). PCA plots were generated
with the normalized samples and group outliers were identified and removed. The
normalized count files that fell within the 95% of the confidence interval were further
processed through DESeq2 to detect differential expression (DE) of TEs and transcripts
among all stages. Gene ontology terms were then assigned to DE transcripts using VisuaL
Annotation Display.

3.2.2 Alignment of RNA-Seq Data Obtained from Clinical and Cell Line
Models Using STAR
We aligned the raw breast cancer progression data to the human genome reference
build HG19 using STAR aligner. STAR’s algorithm [21] uses a two-step approach. STAR
aligns the first portion, or seed, of a read to a reference genome up to the maximum
mappable length (MML) of the read then aligns the left-over portion, second seed, of the
read, up to its MML. After the read is completely aligned, STAR joins the two, or more,
seeds together and scores them based off a user-defined penalty for mismatches,
insertions, and deletions. The “merged” seeds with the highest score are chosen as the
correct alignment of a read. This approach allows for quick and easy annotation of multimapping reads with their own alignment scores. --seedSearchStartLmax 50 –
seedSearchStartLmaxOverLread 1.0 –seedSearchLmax 0 –seedMultimapNmax 10000
–seedPerReadMax 1000 –seedPerWindowMax 50 –seedNonoLociPerWindow 10 –
alignIntronMin 21 –alignIntronMax 0 –alignMatesGapMax 0 –alignSJoverhangMin 5
–alignSJDBoverhangmin

3

–alignSpliceMateMapLmin
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0

–

alignSplicedMateMapeLminOverLmate 0.66 –alignWindowsPerReadNmax 10000 –
alignTranscriptsPerWindowNmax 100 –alignTranscriptsPerReadNmax 10000 –
alignEndsType Local

3.2.3 Quality Control Procedure
To detect and ultimately eliminate outliers of the normalized count files produced
from the featureCounts program we utilized ClustVis. This tool is a web graphical
interface built on many R packages that produces Principal Component Analysis plots
from a data matrix. The tool can handle high dimensional data with many ways to input,
such as copy and paste or upload [22].

3.2.5 Differential Expression Analysis – DESeq2
DESeq2 is an R package that requires raw counts in a data matrix. The program
normalizes the raw counts through a general linear model to account for differences in
sequencing depth [23]. DESeq2 assumes the normalize counts fit a negative binomial
distribution, then adjusts the distribution through unique Empirical Bayes methods to
account for low count variability. DESeq2 also uses Empirical Bayes on log-fold change
estimates to reduce false positives [24]. Within R, the “raw count data” was imported as
a matrix along with a “DataFrame” that had a column which annotates the columns of the
imported matrix. A DESeqDataSet was generated with these imported files using the
DESEq2

function

DESeqDataSetFromMatrix(countData=”raw

count

data”,

colData=”DataFrame”, design=~0 + Stage). The names in the quotation marks are
arbitrary and assigned by the user when importing the corresponding files all quotation
marks should be removed when using the functions in R. The design argument within the
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function is a formula which expresses how the counts for each gene depend on the
variables in colData. Here, the design formula of ~0 + Stage will build a results table and
plot all experimental group comparisons. The data was filtered to keep only genes that
had at least 4 counts between at least 10 samples generating the function keep <rowSums(counts(“name_DESEQDataSetFromMatrix”)>4) >=10 and applying it to
“name_DESEQDataSetFromMatrix”

with

name_DESEQDataSetFromMatrix[keep,].

name_DESEQDataSetFromMatrix
The

DE

analysis

was

called

<using

DESeq(“name_DESEQDataSetFromMatrix”).

3.2.6 VLAD Gene Ontology Analysis of DE Output
VLAD [25], accessible via MGI web portal, is a powerful tool to find common
functional

themes

in

the

lists

of

genes

by

analyzing

statistical

over-

or

underrepresentation of ontological annotations. Currently, users can choose among Gene
Ontology (GO) [26] annotations for human genes, Gene Ontology and Mammalian
Phenotype Ontology (MP) [27] annotations for mouse genes, or upload a file of custom
annotations (in open biomedical ontology [28] known as ‘obo’ format). Unlike other
packages for ontological enrichment, VLAD allows analysis of more than one query (i.e.,
several lists of genes may be analyzed and visualized simultaneously), as well as permits
user to provide own “universe set”, i.e. gene list to test queries. For GO analysis, we
searched for overrepresentation among terms with experimental evidence (i.e., codes
EXP, “Inferred from experiment”; IDA, “Inferred from direct assay”; IMP, “Inferred from
mutant phenotype”; TAS, “Traceable author statement”). Here we analyzed the genes that
were differentially expressed in the disease state when compared to normal. The output
settings for VLAD was set to show the top 10 GO term nodes. Additional GO analysis was
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done on only the shared genes that had significantly differentially expression between all
three disease stages.

3.3 Results
3.3.1 Expression of Transcripts Across Cancer Progression
The number of downregulated, when compared to normal, differentially expressed
transcripts increased at each stage starting with atypia (224) to DCIS (1026) to IDC
(1797). The number of upregulated when compared to normal increased at each stage
starting with atypia (208) to DCIS (1133) to IDC (1923). The number of upregulated genes
were greater than the number of downregulated genes at each stage except for atypia. All
three disease states had 71 genes in common that were upregulated and 107
downregulated. Atypia shared 41 and 23 upregulated genes and 28 and 29 downregulated

Figure 3.2 Venn Diagram of Differentially Expressed Transcripts. The number in each circle
represents the amount of significant differentially expressed genes between comparisons to normal.
The overlapping number is the mutual differentially expressed genes between the comparisons. The
nonoverlapping numbers are the unique differentially expressed genes to the stage A. Increased
expression. B. Decreased expression. (Unpublished)
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genes with DCIS and IDC, respectively. DCIS and IDC shared 480 upregulated and 652
downregulated genes (Figure 3.2).

3.3.2 Expression of All TEs Across Cancer Progression
The percent of transcriptome made up by TEs varied from each stage. Normal samples
had ~14% of their transcriptome derived from TEs. Atypia, DCIS and IDC stages had 16%,
31%, and 24% of their transcriptome derived from TE sequences, respectively (Figure
3.3). The most abundant TE in the transcriptome was by far SINE Alus, followed by LINE
L1 elements (Figure 3.3). Differential expression analysis with DESeq2 revealed a total of
91 TEs were differentially expressed in atypia when compared to normal, 50 upregulated
and 41 downregulated (Table 3.1). DCIS had 93 DE TEs with 52 downregulated and 41
upregulated. IDC had 90 DE TEs with 38 downregulated and 52 upregulated (Table 3.1).

Figure 3.3 Gene transcriptome and TE transcriptome. Total transcriptome represents of all reads
mapped for each stage. TE transcriptome applies to only the portion of TEs mapped. Labels inside
the donut charts N, A, D, and I are normal, atypia, DCIS, IDC, respectively. (Unpublished)
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Figure 3.4 Venn Diagram of Differentially Expressed Transposable Elements. The number in each
circle represents the amount of significant differentially expressed TEs between comparisons to
normal. The overlapping number is the mutual differentially expressed TEs between the
comparisons. The nonoverlapping numbers are the unique differentially expressed TEs to the
stage A. Increased expression. B. Decreased expression. (Unpublished)

Differentially Expressed TE Classes in Each Stage vs Normal
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Figure 3.5 Differentially Expressed TEs. The percent of differentially expressed TEs for each stage
when compared to normal. N, A, D, I are normal, atypia, DCIS, IDC, respectively. (Unpublished)

All three stages had 14 TEs downregulated and 8 TEs upregulated in common. Atypia
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shared 6 upregulated TEs and 6 downregulated TEs with DCIS and only 3 upregulated
TEs with IDC (Figure 3.4). The most differentially expressed TEs are derived from LTR
retrotransposons (Figure 3.5).

Table 3.1 Differentially Expressed TEs for Each Stage
Normal vs Atypia TE Differential Expression
Decreased Expression
Increased Expression
Gene ID
mean counts
log2fc
Gene ID
mean counts
Arthur1A
88.31144
-1.19761
L1P
0.980082
LTR26
42.94001
-0.84414
MER72B
17.07958
MER9B
3.946216
-0.71463
LTR1B
1557.219
LTR47B
38.77274
-0.70031
MER126
3.376455
MER75A
5.174508
-0.67639
MER65B
73.24935
LTR45B
20.86345
-0.66146
Charlie7a
491.628
LTR31
33.38377
-0.64127
LTR80A
5.056746
MER92A
26.71537
-0.63421
LTR21B
271.0958
MER9a1
5.039478
-0.63007
MLT1H1-int
7.397377
UCON8
1.339151
-0.61849
UCON28a
2.022031
LTR33C
30.45387
-0.60741
L1P4e
6.793599
MER30
3304.641
-0.58869
MER129
0.75144
Kanga1
31.79583
-0.55766
Eulor5A
1.094842
LTR5
11.39286
-0.50638
L1P3b
1.846388
MER4B
126.7963
-0.50568
L1P4b
4.984204
Charlie26a
48.28848
-0.48566
MER34D
5.348247
AluYc3
422.5673
-0.48151
REP522
11.35279
PABL_B-int
26.668
-0.47848
LTR35B
9.102511
MER30B
93.93234
-0.4441
HERVL66-int
6.845766
LTR22A
32.48954
-0.43086
L1M3b
22.152
LTR57
149.023
-0.42003
HERV9-int
54.99825
MLT1G1
317.0708
-0.41623
MER117
474.3747
LTR2C
70.10864
-0.40906
MLT1F1-int
5.487104
LTR7Y
13.69006
-0.40684
L1M3d
18.64688
LTR71A
15.19133
-0.39458
PRIMAX-int
11.4911
MamSINE1
30.62804
-0.37619
MER34C_
16.67257
LTR71B
36.38883
-0.37396
HERVK9-int
23.67049
MER67B
22.97493
-0.36667
MADE1
41.47423
LFSINE_Vert
34.7053
-0.35311
Helitron1Nb_Mam
7.396498
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log2fc
1.128909
0.916284
0.902702
0.785418
0.766244
0.690044
0.686491
0.671783
0.660866
0.633624
0.623929
0.618061
0.587229
0.582259
0.578542
0.523346
0.516018
0.511705
0.509542
0.507322
0.504146
0.493
0.478243
0.477292
0.46363
0.463589
0.453221
0.441296
0.438009

Table 3.1 Differentially Expressed TEs for Each Stage continued

Gene ID

Normal vs Atypia TE Differential Expression
Decreased Expression
Increased Expression
mean counts
log2fc
Gene ID
mean counts

LTR19C
MER34A1
MER57A-int
MLT2B3
MER4B-int
HERVE-int
MER4D1
LTR33
MSTB
L1MEd
MLT1F
MER34A

Gene ID
Arthur1A
LTR47B
LTR71A
LTR22B
LTR33C
MER136
LTR26
UCON8
MER87B
Kanga1
MLT1H1
LTR7Y
MER75A

23.57059
36.36152
117.5749
137.7282
142.0717
64.99913
86.04822
335.7643
583.0843
775.946
206.4737
62.62155

-0.3418
-0.34042
-0.33519
-0.33277
-0.3311
-0.30938
-0.30104
-0.28012
-0.27168
-0.25511
-0.22582
-0.21991

Charlie25
40.98877
Charlie13b
8.221666
Charlie13a
16.22747
LTR33B
25.14249
LTR83
17.48438
HUERS-P3-int
30.09348
MER61C
110.6387
HUERS-P3b-int
29.15117
L1MCc
123.1923
L1MEg1
24.70014
L1M3a
53.65659
MER115
104.8611
MER34B-int
58.07753
PABL_A-int
25.69041
Kanga1d
22.4711
L1PA4
387.2464
MER83
32.36049
MER20B
105.1399
LTR50
81.84953
L1MA8
529.3803
L1MC1
1290.854
Normal vs DCIS TE Differential Expression
Decreased Expression
Increased Expression
mean counts
log2fc
Gene ID
mean counts
88.31144
-2.09674
LSAU
11.58124
38.77274
-1.35732
MER65B
73.24935
15.19133
-1.24783
LTR1B
1557.219
9.025771
-1.17259
L1P
0.980082
30.45387
-1.09236
LTR54
31.52492
7.400865
-1.08447
MER117
474.3747
42.94001
-1.02994
LTR16D2
5.696531
1.339151
-0.84387
REP522
11.35279
93.73568
-0.82151
LTR48B
50.26594
31.79583
-0.79467
L1P3b
1.846388
563.7559
-0.79164
BC200
41.36107
13.69006
-0.72183
MER57C2
13.24137
5.174508
-0.70979
MLT1E1
43.42278
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log2fc
0.423518
0.416912
0.411792
0.397622
0.39567
0.389583
0.373984
0.366634
0.359872
0.349497
0.322185
0.321623
0.315648
0.312568
0.310897
0.30876
0.271639
0.237609
0.23303
0.217301
0.168575

log2fc
1.715874
1.186762
1.178637
0.812512
0.800878
0.785503
0.784678
0.780176
0.699477
0.696507
0.688127
0.658465
0.653669

Table 3.1 Differentially Expressed TEs for Each Stage continued
Normal vs DCIS TE Differential Expression
Decreased Expression
Increased Expression
Gene ID
mean counts
log2fc
Gene ID
mean counts
LTR14C
17.30651
-0.70115
LTR38B
18.4308
LTR14B
32.79084
-0.70005
MER50C
12.59559
MER11A
82.26047
-0.6841
LTR19A
40.4795
LTR31
33.38377
-0.66541
AluYd8
17.5837
LTR77
11.17067
-0.63033
MER72B
17.07958
HERVK3-int
42.23356
-0.61771
MER126
3.376455
LTR45B
20.86345
-0.61327
MER34D
5.348247
HERVK14C-int
29.48786
-0.60785
MLT1H1-int
7.397377
PABL_B-int
26.668
-0.60702
Tigger14a
137.99
LTR2B
64.26932
-0.57812
MER34B-int
58.07753
Ricksha_b
6.586193
-0.56754
LTR45C
95.388
Charlie5
140.7848
-0.56399
MER57D
85.42611
LTR47A
122.1144
-0.56255
UCON28a
2.022031
LTR18B
554.2769
-0.56142
HERV1_LTRc
2.540698
Tigger16a
27.83332
-0.52133
UCON12
0.769677
LTR7
269.9551
-0.52074
L1M3b
22.152
MLT1J
1437.407
-0.50306
AluYk12
15.57561
LTR52
74.46954
-0.50299
HERV3-int
59.02318
LTR71B
36.38883
-0.48756
MLT2C1
91.98793
LTR5A
276.3234
-0.48653
LTR35B
9.102511
MamSINE1
30.62804
-0.48147
MER57E3
7.900197
MLT2B3
137.7282
-0.47711
MLT1A-int
18.54955
HERVE-int
64.99913
-0.46512
LTR54B
79.42418
LTR19C
23.57059
-0.45116
MER66B
52.91956
MER113B
15.63274
-0.44184
FAM
2381.384
LTR16B
29.38154
-0.4357
MLT2D
118.0271
MER74C
15.92237
-0.43204
MER54A
106.9699
MER34A1
36.36152
-0.42523
MER61A
74.20794
Tigger2a
120.1334
-0.4221
MIRb
9179.493
-0.39734
MER4D1
86.04822
-0.38151
MER63C
92.03893
-0.37102
L1MEg2
52.67794
-0.35629
THE1D
290.7215
-0.33133
MER5A1
216.3702
-0.32085
MER68
171.6801
-0.31175
Charlie19a
41.869
-0.31096
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log2fc
0.633847
0.629959
0.62591
0.621454
0.617702
0.612485
0.579943
0.579398
0.578615
0.578239
0.569887
0.569602
0.567579
0.5644
0.563383
0.556069
0.550366
0.547919
0.543026
0.51087
0.507352
0.482331
0.46405
0.463957
0.463382
0.453338
0.447586
0.445774

Table 3.1 Differentially Expressed TEs for Each Stage continued
Normal vs IDC TE Differential Expression
Decreased Expression
Increased Expression
Gene ID
mean counts
log2fc
Gene ID
mean counts
Arthur1A
88.31144
-2.22411
MSR1
83.43339
LTR33C
30.45387
-1.43662
LTR10B1
29.21936
LTR47B
38.77274
-1.38331
HERVI-int
25.60405
LTR26
42.94001
-1.19
HERV3-int
59.02318
LTR11
4.407613
-1.09968
LTR12B
59.98547
UCON2
6.113835
-1.02234
LTR35B
9.102511
LTR22B
9.025771
-0.94438
UCON28b
2.305686
LTR14C
17.30651
-0.93774
MER57D
85.42611
Kanga1
31.79583
-0.85578
REP522
11.35279
UCON8
1.339151
-0.76292
MER126
3.376455
LTR31
33.38377
-0.7259
MLT2B4
175.1764
MER136
7.400865
-0.71672
MLT1E1
43.42278
HERVK14C-int
29.48786
-0.71089
L1P3b
1.846388
LTR43B
5.763048
-0.63699
ACRO1
2.914097
LTR18B
554.2769
-0.62973
MamRep4096
119.5002
LTR5A
276.3234
-0.60201
MER117
474.3747
LTR81AB
20.83903
-0.59248
MER72B
17.07958
ORSL-2a
4.846807
-0.55552
LSAU
11.58124
LTR77
11.17067
-0.5368
LTR3B
83.12914
LTR45B
20.86345
-0.53585
LTR48B
50.26594
HAL1-3A_ME
133.1612
-0.51514
MLT-int
19.4105
LTR71B
36.38883
-0.51507
L1P
0.980082
MER57E1
124.6372
-0.50986
LTR89
91.29133
MER11A
82.26047
-0.50613
MER91B
56.85263
MamSINE1
30.62804
-0.48073
MER34B-int
58.07753
HERVE-int
64.99913
-0.44387
Charlie7a
491.628
LTR71A
15.19133
-0.43595
LTR45C
95.388
MER74C
15.92237
-0.43385
MER4A1
209.7975
LTR24B
16.62667
-0.4284
UCON4
13.45696
MER106B
34.97379
-0.42594
SVA_F
177.8978
L1M3f
84.27394
-0.41599
MamGypLTR2c
47.37201
Tigger10
114.5806
-0.40669
MER54A
106.9699
Charlie5
140.7848
-0.39116
LTR66
58.15395
MER34A1
36.36152
-0.3804
LTR10E
26.02065
MER51-int
56.46602
-0.37199
MER63B
273.1816

97

log2fc
1.459245
1.313723
1.18361
1.05755
1.01489
0.95987
0.923133
0.904658
0.885975
0.857979
0.806983
0.731794
0.731274
0.723884
0.72054
0.704449
0.691256
0.665175
0.633166
0.612501
0.608322
0.590872
0.57424
0.564587
0.560957
0.559075
0.554385
0.54857
0.505048
0.48302
0.474557
0.467797
0.460548
0.449156
0.447306

Table 3.1 Differentially Expressed TEs for Each Stage continued

Gene ID
LOR1b
MSTB
SVA_D

Normal vs IDC TE Differential Expression
Decreased Expression
Increased Expression
mean counts
log2fc
Gene ID
mean counts
55.24626
-0.33469
MER113A
135.9744
583.0843
-0.25025
Arthur1C
12.71432
170.6297
-0.22132
MER1B
437.3959
MER31B
73.26301
MLT2C1
91.98793
MER61C
110.6387
Tigger11a
440.1543
MER68-int
14.18787
LTR79
87.83257
Charlie16a
109.2027
MER102b
527.5156
MLT1C
1671.165
MLT1G
106.6917
MER6A
97.45217
MER115
104.8611
L2c
6367.266
L1MB5
967.9758
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log2fc
0.445428
0.437378
0.414795
0.412004
0.401928
0.401604
0.399371
0.38088
0.380088
0.374402
0.354318
0.343778
0.304594
0.303702
0.290959
0.233836
0.163403

3.3.3 VLAD Gene Ontology Output
3.3.3a Examples of Validation of Cancer Pathways
The top 10 GO molecular functions terms for transcripts that were increased in
atypia compared to normal centered around transmembrane transported activity (Table
3.2 and Figure 3.6). In DCIS the GO analysis of transcripts that were increased compared
to normal revealed terms for not only transmembrane transporter activity, but also
GTPase binding to include ras GTPase binding and intracellular trafficking (Table 3.2 and
Figure 3.7). The increased expressed transcripts from IDC had an overwhelming number
of cellular components GO terms for extracellular pathways. Furthermore, the molecular
function GO terms for IDC involved cell adhesion, extra cellular matrix constituents, and
collagen binding, as well as, growth factor binding and protein kinase binding (Table 3.2
and Figure 3.8).
A

Figure 3.6 Top Ten Overrepresented Gene Ontology Terms of Upregulated Differentially
Expressed Genes in Atypia. A. Biological Processes. B. Cellular Components. C. Molecular
Functions (Unpublished)
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B

C

Figure 3.6 (continued) Top Ten Overrepresented Gene Ontology Terms of Upregulated
Differentially Expressed Genes in Atypia. A. Biological Processes. B. Cellular Components. C.
Molecular Functions (Unpublished)
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B

A

C

Figure 3.7 Top Ten Overrepresented Gene Ontology Terms of Upregulated Differentially Expressed
Genes in DCIS. A. Biological Processes. B. Cellular Components. C. Molecular Functions (Unpublished)
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A

B

C

Figure 3.8 Top Ten Overrepresented Gene Ontology Terms of Upregulated Differentially Expressed
Genes in IDC. A. Biological Processes. B. Cellular Components. C. Molecular Functions (Unpublished)
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3.3.3b Examples of Novel Pathways
For example, GO analysis of DE gene in DCIS and IDC when compared to normal
produced outputs that reveal genes in the category to “Response to Virus” under the
biological process hierarchy and under the molecular function hierarchy, genes belonging
to Interferon Activation Response terms are significantly overrepresented (Table 3.2 and
Figures 3.7 & 3.8). Additionally, the 2’-5’-oligoadenylate synthetase activity term for
molecular function is present for both DCIS and IDC, which indicates this pathway is
upregulated at a precancerous stage before malignancy occurs (Table 3.2 and Figures 3.7
& 3.8). This is a novel target pathway to inhibit and mitigate cellular transformation to
malignancy.
3.3.3c Conserved Transcripts
A GO analysis of the 71 conserved transcripts that had an increase in expression
across all stages of cancer compared to normal, revealed many terms associated with
regulating the differentiation processes, transport activity, and hormone binding.
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Table 3.2 Top 10 GO Terms of DE Genes for Each Stage Compared to Control
and Each Category

Atypia
TermID

GO:0060971

GO:0048468
GO:0060562

GO:0060972

GO:0030856
GO:0008016
GO:0006811

GO:1990778

GO:0051239
GO:0099637

Term
embryonic heart
tube left/right
pattern formation

cell development
epithelial tube
morphogenesis

left/right pattern
formation
regulation of
epithelial cell
differentiation
regulation of
heart contraction
ion transport
protein
localization to cell
periphery
regulation of
multicellular
organismal
process
neurotransmitter
receptor transport
Atypia

TermID

GO:0005891
GO:0097458

GO:1902495

Term
voltage-gated
calcium channel
complex
neuron part
transmembrane
transporter
complex

Biological Processes
DCIS
TermID
Term
cellular
response to
GO:0071357 type I interferon
type I interferon
signaling
GO:0060337 pathway
response to
GO:0034340 type I interferon

GO:0030198

GO:0046903 secretion

GO:0019221

regulation of
GO:0032879 localization
GO:0006811 ion transport
GO:0051179 localization
lipid metabolic
GO:0006629 process

regulation of
GO:0050790 catalytic activity
response to
GO:0009615 virus
Cellular Components
DCIS
TermID
Term

GO:0005737 cytoplasm

IDC
TermID

GO:0043062
GO:0002376

Term
extracellular
matrix
organization
extracellular
structure
organization
immune system
process
cytokinemediated
signaling
pathway

GO:0046903 secretion
regulation of
GO:0032879 localization
regulated
GO:0045055 exocytosis

GO:0032940 secretion by cell
regulation of
multicellular
organismal
GO:0051239 process
response to
GO:0034097 cytokine
IDC
TermID

Term

GO:0044444 cytoplasmic part

GO:0031982 vesicle
extracellular
GO:0044421 region part

GO:0031982 vesicle

extracellular
GO:0005615 space
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Table 3.2 Top 10 GO Terms of DE Genes for Each Stage Compared to Control
and Each Category continued

Atypia
TermID
GO:1990351
GO:0034704
GO:0034702
GO:0008282
GO:0044459
GO:0098590
GO:0043005
GO:0034703

Term
transporter
complex
calcium channel
complex
ion channel
complex
inward rectifying
potassium channel
plasma membrane
part
plasma membrane
region
neuron projection
cation channel
complex
Atypia

Cellular Components
DCIS
TermID
Term
GO:0044425
GO:0044459
GO:0016020
GO:0031410
GO:0097708
GO:0070062
GO:0012505

membrane part
plasma
membrane part

Term
extracellular
GO:0031012 matrix
extracellular
GO:0005576 region

membrane
cytoplasmic
vesicle
intracellular
vesicle
extracellular
exosome
endomembrane
system

GO:0005737 cytoplasm
extracellular
GO:0070062 exosome
extracellular
GO:1903561 vesicle
extracellular
GO:0043230 organelle
cytoplasmic
GO:0044444 part

Molecular Function
DCIS
TermID
Term
2'-5'oligoadenylate
synthetase
GO:0001730 activity

TermID

Term

GO:0022857

transmembrane
transporter activity

GO:0005245

voltage-gated
calcium channel
activity

GO:0022857

GO:0005215

transporter activity

GO:0016822

GO:0022843

voltage-gated
cation channel
activity

GO:0016823

IDC

transmembrane
transporter
activity
hydrolase
activity, acting on
acid carboncarbon bonds
hydrolase
activity, acting on
acid carboncarbon bonds, in
ketonic
substances
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TermID

IDC
TermID

Term

GO:0005515 protein binding
extracellular
matrix
structural
GO:0005201 constituent

cytoskeletal
GO:0008092 protein binding

cell adhesion
molecule
GO:0050839 binding

Table 3.2 Top 10 GO Terms of DE Genes for Each Stage Compared to Control
and Each Category continued

Atypia
TermID

GO:0015075

GO:0005216
GO:0022838

GO:0022839
GO:0022836

GO:0046873
GO:0015267

GO:0022803

GO:0015318

Molecular Function
DCIS
TermID
Term

Term
ion
transmembrane
transporter
activity

Ras GTPase
GO:0017016 binding

ion channel
activity
substrate-specific
channel activity

GO:0005515 protein binding
small GTPase
GO:0031267 binding

ion gated channel
activity
GO:0051020
gated channel
activity
GO:0016491
metal ion
transmembrane
transporter
activity
GO:0019899
channel activity
passive
transmembrane
transporter
activity
inorganic molecular entity
transmembrane transporter
activity

GTPase binding
oxidoreductase
activity

enzyme binding

IDC
TermID

GO:0019838

GO:0048407
GO:0042802

GO:0001730

Term

growth factor
binding
platelet-derived
growth factor
binding
identical protein
binding
2'-5'oligoadenylate
synthetase
activity

GO:0005518 collagen binding

protein kinase
GO:0019901 binding

3.4 Discussion
Through in silico methods, we determined that TEs made up a large portion of the
transcriptome with the highest proportion in DCIS. The highest number of statistically
significant differentially expressed TEs were LTRs. The highest number of LTRs were
found to be differentially expressed at the DCIS stage.
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Conserved transcripts, such as, HOTAIR [29-31], TMEM8A [32, 33], S100A7 [34,
35], and PAX genes [36-39] had increased expression in disease state compared to
normal, are known oncogenes. Furthermore, GO analysis revealed oncogenic processes
and pathways activated before and during the disease state, as well as novel pathways that
may highlight interesting research to be further explored. Atypia was heavily populated
with transporter activity GO terms, a hallmark of cancer stem cells [40]. Many of these
terms were also found in DCIS and IDC. However, DCIS also produced terms involving
GTPase binding, specifically ras GTPase, a well-known oncogene, and intracellular
trafficking. Earlier reports of intracellular trafficking dysregulation in DCIS corroborates
these findings [41]. The diversification of IDC GO terms into well-known oncogenic
terms, such as, kinase binding, extracellular organization, growth factor binding, cytokine
signaling, cell adhesion, and collagen binding indicates the invasive nature of the tissues
sampled.
Novel pathways include the activity of 2’-5’-oligoadenylate synthetase which is
known to induce an intrinsic antiviral state [42]. Additionally, many interferon response
terms are present, which the expression of ERVs are known to induce, followed by an
antiviral cell state [43-45]. These findings corroborate ERVs being the most differentially
expressed transposable element and may indicate important implications in the role
ERVs are playing in breast cancer progression.
Therefore, we have demonstrated a TE signature during breast cancer progression
at the early stages, which indicates LTRs as the most abundantly differentially expressed.
Furthermore, interferon responses as indicated VLAD GO analysis of abundant
differentially expressed coding regions corroborates LTR endogenous retroviral activity,
which was further substantiated in previous studies.
107

3.5 References
1.
2.

3.
4.

5.
6.
7.

8.
9.

10.

11.
12.
13.

14.
15.

16.

17.

Hortobagyi, G.N., et al., Breast, in AJCC Cancer Staging Manual, M.B. Amin, et al.,
Editors. 2017, Springer: New York. p. 589-636.
Page, D.L., et al., Continued local recurrence of carcinoma 15–25 years after a diagnosis
of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer, 1995.
76(7): p. 1197-1200.
Page, D.L., et al., Intraductal carcinoma of the breast: follow‐up after biopsy only.
Cancer, 1982. 49(4): p. 751-758.
Sanders, M.E., et al., The natural history of low‐grade ductal carcinoma in situ of the
breast in women treated by biopsy only revealed over 30 years of long‐term follow‐up.
Cancer, 2005. 103(12): p. 2481-2484.
Narod, S.A., et al., Breast cancer mortality after a diagnosis of ductal carcinoma in situ.
JAMA oncology, 2015. 1(7): p. 888-896.
Esserman, L. and C. Yau, Rethinking the standard for ductal carcinoma in situ treatment.
JAMA oncology, 2015. 1(7): p. 881-883.
Casbas-Hernandez, P., et al., Role of HGF in epithelial–stromal cell interactions during
progression from benign breast disease to ductal carcinoma in situ. Breast Cancer
Research, 2013. 15(5): p. R82.
Huang, S., et al., Changes in gene expression during the development of mammary
tumors in MMTV-Wnt-1 transgenic mice. Genome biology, 2005. 6(10): p. R84.
Klein, A., et al., Comparison of gene expression data from human and mouse breast
cancers: identification of a conserved breast tumor gene set. International journal of
cancer, 2007. 121(3): p. 683-688.
Knudsen, E.S., et al., Progression of ductal carcinoma in situ to invasive breast cancer is
associated with gene expression programs of EMT and myoepithelia. Breast cancer
research and treatment, 2012. 133(3): p. 1009-1024.
Kretschmer, C., et al., Identification of early molecular markers for breast cancer.
Molecular cancer, 2011. 10(1): p. 15.
Lee, S., et al., Differentially expressed genes regulating the progression of ductal
carcinoma in situ to invasive breast cancer. Cancer research, 2012.
Evsikov, A.V. and D. Solter, Comment on &quot; &#039;Stemness&#039;:
Transcriptional Profiling of Embryonic and Adult Stem Cells&quot; and &quot;A Stem
Cell Molecular Signature&quot; (II). Science, 2003. 302(5644): p. 393.
Chen, J.-M., et al. Genomic rearrangements in inherited disease and cancer. in Seminars
in cancer biology. 2010. Elsevier.
Konkel, M.K. and M.A. Batzer. A mobile threat to genome stability: The impact of nonLTR retrotransposons upon the human genome. in Seminars in cancer biology. 2010.
Elsevier.
Romanish, M., C. Cohen, and D. Mager. Potential mechanisms of endogenous retroviralmediated genomic instability in human cancer. in Seminars in cancer biology. 2010.
Elsevier.
Contreras-Galindo, R., et al., Human endogenous retrovirus K (HML-2) elements in the
plasma of people with lymphoma and breast cancer. Journal of virology, 2008. 82(19): p.
9329-9336.

108

18.
19.
20.

21.
22.

23.
24.
25.
26.
27.

28.
29.
30.
31.

32.
33.
34.
35.
36.
37.
38.

A.F.A. Smit, R.H.P.G. RepeatMasker. 11/21/2018 [cited 2018; 4.0.8:[Available from:
www.repeatmasker.org.
Barrett, T., et al., NCBI GEO: archive for functional genomics data sets—update. Nucleic
acids research, 2012. 41(D1): p. D991-D995.
Liao, Y., G.K. Smyth, and W. Shi, featureCounts: an efficient general purpose program
for assigning sequence reads to genomic features. Bioinformatics, 2013. 30(7): p. 923930.
Dobin, A., et al., STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 2013.
29(1): p. 15-21.
Metsalu, T. and J. Vilo, ClustVis: a web tool for visualizing clustering of multivariate
data using Principal Component Analysis and heatmap. Nucleic acids research, 2015.
43(W1): p. W566-W570.
McCullagh, P. and J.A. Nelder, Generalized linear models. Vol. 37. 1989: CRC press.
Love, M.I., W. Huber, and S. Anders, Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol, 2014. 15(12): p. 550.
Richardson, J.E. and C.J. Bult, Visual annotation display (VLAD): a tool for finding
functional themes in lists of genes. Mammalian Genome, 2015. 26(9): p. 567-573.
Ashburner, M., et al., Gene Ontology: tool for the unification of biology. Nature Genetics,
2000. 25: p. 25.
Smith, C.L., C.-A.W. Goldsmith, and J.T. Eppig, The Mammalian Phenotype Ontology
as a tool for annotating, analyzing and comparing phenotypic information. Genome
Biology, 2004. 6(1): p. R7.
Smith, B., et al., The OBO Foundry: coordinated evolution of ontologies to support
biomedical data integration. Nature Biotechnology, 2007. 25: p. 1251.
Gupta, R.A., et al., Long non-coding RNA HOTAIR reprograms chromatin state to
promote cancer metastasis. 2010. 464(7291): p. 1071.
Pawłowska, E., J. Szczepanska, and J.J.I.j.o.m.s. Blasiak, The long noncoding RNA
HOTAIR in breast cancer: does autophagy play a role? 2017. 18(11): p. 2317.
Sørensen, K.P., et al., Long non-coding RNA HOTAIR is an independent prognostic
marker of metastasis in estrogen receptor-positive primary breast cancer. 2013. 142(3):
p. 529-536.
Wang, Y., et al., Gene-expression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. 2005. 365(9460): p. 671-679.
Zang, H., et al., Identification of upstream transcription factors (TFs) for expression
signature genes in breast cancer. 2017. 33(3): p. 193-198.
Al-Haddad, S., et al., Psoriasin (S100A7) expression and invasive breast cancer. 1999.
155(6): p. 2057-2066.
Emberley, E.D., L.C. Murphy, and P.H.J.B.C.R. Watson, S100A7 and the progression of
breast cancer. 2004. 6(4): p. 153.
Buttiglieri, S., et al., Role of Pax2 in apoptosis resistance and proinvasive phenotype of
Kaposi's sarcoma cells. 2004. 279(6): p. 4136-4143.
Muratovska, A., et al., Paired-Box genes are frequently expressed in cancer and often
required for cancer cell survival. 2003. 22(39): p. 7989.
Qun, L., et al., Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast
carcinomas. 2009. 122(22): p. 2763-2769.

109

39.
40.
41.
42.
43.
44.
45.

Robson, E.J., S.-J. He, and M.R.J.N.R.C. Eccles, A PANorama of PAX genes in cancer
and development. 2006. 6(1): p. 52.
Dean, M., T. Fojo, and S. Bates, Tumour stem cells and drug resistance. Nature Reviews
Cancer, 2005. 5(4): p. 275.
Wulfkuhle, J.D., et al., Proteomics of human breast ductal carcinoma in situ. 2002.
62(22): p. 6740-6749.
Lohöfener, J., et al., The activation mechanism of 2′-5′-oligoadenylate synthetase gives
new insights into OAS/cGAS triggers of innate immunity. 2015. 23(5): p. 851-862.
Chiappinelli, K.B., et al., Inhibiting DNA methylation causes an interferon response in
cancer via dsRNA including endogenous retroviruses. 2015. 162(5): p. 974-986.
Haffner, M.C., et al., Hypomethylation, endogenous retrovirus expression, and interferon
signaling in testicular germ cell tumors. 2018. 115(37): p. E8580-E8582.
Hurst, T.P. and G.J.J.o.G.V. Magiorkinis, Activation of the innate immune response by
endogenous retroviruses. 2015. 96(6).

110

Chapter Four:
Regulation of Retrotransposon Activity in an In Vitro Model

4.1 Introduction
Transposable elements make up ~45% of the human genome. Interestingly,
retrotransposons, a subgroup of transposable elements, make a larger portion of the
human genome than protein coding genes. They are mobile genetic elements which can
insert themselves into other genomic locations using a copy and paste mechanism, as
reviewed in chapter 1. If left unchecked, the retrotransposition of these elements may
become deleterious and hinder host survival. The role of retrotransposons as a mutagenic
agent is well known and the accumulation of retrotransposon-induced mutations in
important genes contributes to oncogenesis [1, 2]. One of the first lines of defense against
retrotransposon activity is DNA methylation[3-7]. Along with other epigenetic repressive
and posttranscriptional mechanisms these host defenses are quite effective[8-10].
However, because of the copy and paste mechanisms utilized by retrotransposons, our
genome is riddled with multiple repeats of identical or highly homologous inserts. A
recent study, using genome-wide microarray approaches that measured DNA
methylation changes in cancerous tissue compared to adjacent normal tissue, found that
disease tissue had highly variable disruption of epigenetic control. Specifically, certain
members of transposon families, such asSVA, HERV, LINe-1-P, ALU, and MaLR, had a
loss of methylation appeared in a stochastic fashion [11]. Here we attempt to gain insight
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into the role of retrotransposons contributions to cancerous events by examining
MCF10A and MCF10DCIS cell lines using pharmacological approaches.

4.1.1 Testing the Roles of Retrotransposons in the Transformation of
Pre-Malignant to Malignant Breast Cancer using pharmacological approach
4.1.1a Pharmacological approach
Until further advancements are made in gene targeted therapy to differentiate
among the numerous copies of transposable elements, alternative approaches must be
examined. As previously mentioned, TEs are primarily regulated by epigenetic
mechanisms. One approach to induce expression of cryptic transcription start sites
encoded by LTRs is to inhibit methyl group availability or DNMT activity [12].
Furthermore, there is experimental evidence that antiretroviral drugs, such as integrase
inhibitors and reverse transcriptase inhibitors, influences endogenous retrovirus activity
[13-16].
4.1.1b Genetic Engineering Approaches
The application of genetic engineering to knockout, knockdown, or even
overexpress genes of interest has revolutionized medical research. Genetic approaches
utilize DNA sequence targeting techniques to regulate the loci of interest. Unfortunately,
TEs have multiple locations within the host genome and a sequence targeted approach
would damage substantial areas of the genome. For example, a single long terminal repeat
family may have thousands of genomic inserts with the same or very highly similar
sequences. For example, the LTR that acts as an alternative promoter for ALK [17] and is
responsible for the transcription initiation of a constituently active isoform found in many
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cancers [18] has > 1,000 non-redundant and 5,000 redundant locations in the human
genome (Figure 4.1) [19].
A

B

Figure 4.1 Alternative Promoter and Nonredundant Genomic Locations of LTR16B2. A
Representation of LTR16B2’s alternative promoter activity in between exons 19 and 20 of ALK. B
Representation of the nonredundant locations of LTR16B2 repeats in the human genome. Each
blue line on chromosomes are a single repeat of LTR16B2. Adapted from Human Endogenous
Retrovirus Database, J Paces, 2019, https://herv.img.cas.cz/

4.1.2 Research Purpose and Approach
The goal of this study is to demonstrate TEs role in the transition from premalignant to malignant breast cancer. We hypothesize that retrotransposon TEs
contribute to the transformation of breast cancer. To test this hypothesis, we utilized
novel and previously established pharmacological techniques to induce TE expression
and inhibit classical TE retrotransposition activity in an immortalized breast cell line and
a breast cancer cell line which has characteristics of an early stage ductal carcinoma. The
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expected outcomes of this study are the characterization of TE expression via effects on
proliferation, migration, and anchorage independent growth.

4.2 Methods
4.2.1 Cell culture conditions of both cell lines
MCF10a and MCF10DCIS cells were cultured in DMEM (Gibco, 316000-034) with
5% horse serum (ATCC 30-2040), EGF (Sigma, E9644) at 20 ng/ml, hydrocortisone
(Sigma, H0888) at 0.5 mg/ml, cholera toxin (Sigma, C8062) at 100 ng/ml, insulin
(Sigma, I6634) at 10ug/ml, and 1% Penicillin-Streptomycin (Gibco, 15140). Cells used for
experiments were passaged every 3 to 4 days and at a passage number between 5 to 30,
the ranges arbitrarily chosen to maintain continuity.

4.2.2 Drugs
To reduce methyl group availability and retrotransposon repression we used SAM
cycle inhibitors 3-Deazanplanocin A (Cayman Chemical Company, 11102), 3Deazaadenosine (Cayman Chemical Company, 9000785), and DNMTi 5-Azacytidine
(Sigma, A2385). To decrease retrotransposon activity, we used integrase inhibitors
Raltegravir (Sigma, CDS023737) and Elvitegravir (Cayman Chemical Company, 17798),
and reverse transcriptase inhibitor Azidothymidine (Sigma, PHR1292). Many of our
drugs used dimethyl sulfoxide (DMSO, Sigma, D4540) as a vehicle.
4.2.2a 3-Deazaneplanocin A (DZNEP)
In vitro studies revealed DZNEP inhibits S-adenosyl-L-3H-methylmethionine and
3-thymidine incorporation at concentration of 700 nM (200ng/mL). At concentrations
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between 500 nM and 1 µM (150 ng/mL and 300 ng/mL) DZNEP also depletes EZH2 and
inhibits trimethylation of lysine 27 on histone 3 (H3k27) [20, 21].
4.2.2b 3-Deazaadenosine (DZA)
The half maximal inhibitory concentration (IC50) of DZA against S-adenosylhomocysteine hydrolase is 4 µM. DZA has unspecific inhibitory activity at concentrations
near 100 µM [22].
4.2.2c 5-Azacytidine (AZA)
At a concentration of 40 µM, AZA replaced ~8% of the cytosines in inhibitory DNA
resulting in 0.6 – 1.8 nM ranges for DNMT inhibition [23].
4.2.2d Raltegravir (RAL)
Endogenous retroviral DNA remains in a pre-integration complex with integrase
after reverse transcription. Integrase snips target DNA at the integration site. Raltegravir
effectively inhibits HIV integrase and HTLV-1 cell-cell infection at concentrations of
20nM to 90nM (IC95 at 31±20 nM) [14, 24]. Furthermore, Raltegravir was effective at
inhibiting HERV-K infection with an IC90 of 0.075 µM [16].
4.2.2e Elvitegravir (ELV)
Second generation integrase inhibitor has a broad antiretroviral activity and
inhibits integrase at concentrations of 0.5-5.8 nM [15].
4.2.2f Azidothymidine (AZT)
Endogenous retroviruses are reverse transcribed from RNA to DNA through their
own viral protein reverse transcriptase. AZT was shown to inhibit recombinant HIV RT
at 0.32 ± 0.11 µM concentrations and endogenous retrotransposons at 16.4 ± 4.21 nM [13,
25, 26].
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4.2.3 Cell Viability & Density Dose-Response Curves
To determine dosage for future experiments, cell viability and density assays were
performed. Briefly, 25 x 103 of MCF10A or MCF10DCIS cells were seeded with drug into
each well of a 24 well plate. All drugs were coded with an alphanumeric nomenclature
before experiments to keep experimenter unaware of treatment groups. After 48 hours in
treatment cells were trypsinized and pelleted then media was aspirated. The cell pellet
was resuspended in fresh media. A 15 µl sample of the resuspension was mixed with
tryphan blue at a 1:1 ratio and cell viability and density was analyzed using a
hemocytometer. The experimental design is clarified in the table below. Cell viability was
determined by dividing the number of live cells by the total number of cells. Cell density
is the total number of live cells.
Table 4.1 Cell viability and density dose-response curve experimental design
Drug Name

Drug

n of Each Drug

Concentrations

Concentration

Volume of 10 µl/ml

4

10 µM, 100 µM

4, 2

DZNEP

0.1, 1, 10 µM

2

DZA

1, 10, 100 µM

2

5-Azacytidine

1, 10, 100 µM

2

Elvitegravir

1, 10, 100 µM

2

Raltegravir

1, 10, 100 µM

2

Azidothymidine

1, 10, 100 µM

2

Vehicle H2O
Vehicle DMSO
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4.2.4 Scratch Assay
4.2.4a Pilot Study
To examine growth rates and migration patterns as an indicator of the metastatic
phenotype we performed scratch/wound healing assays. Pilot studies of the scratch assay
were done in 24 well plates with each cell line, MCF10A and MCF10DCIS, seeded at 5 x
104 in cell culture media and allowed to reach confluency. When cells reached confluency,
a scratch was made down the center of each well with a sterile 200 µl pipette tip. Cells
were washed and media with treatment was added to labelled wells. Each treatment had
3 wells in the 24 well plate (Table 4.2). Images were taken at time point 0 and every 6
hours till the 24-hour time point to analyze area of scratch.
Table 4.2 Scratch assay pilot study experimental design
Drug Name

Drug Concentration

n

Vehicle H2O

Volume of 10 µl/ml

3

10 µM

3

1 µM

3

DZA

10 µM

3

5-Azacytidine

10 µM

3

Elvitegravir

10 µM

3

Azidothymidine

10 µM

3

Vehicle DMSO
DZNEP

4.2.4b WoundMakerTM
To further examine growth rates and migration or migration (drug + Mitomycin)
alone we performed a wound/scratch assay using the Essen WoundMaker TM, a 96-pin
wound making tool. Briefly, 25 x 103 cells per well were seeded in cell culture media in all
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96 wells. After 18hrs in an incubator at 37°C with 5% CO2 the WoundMakerTM was utilized
to create wounds in all wells. Cells were immediately washed twice with culture media
(100 µl per well). Drugs labeled in a way to ensure blind experimental settings was applied
to respectively labeled wells. The 96 well plate was then allowed to equilibrate in an
IncuCyte® incubator before being imaged for time point 0 and every 6 hours for 24 hours.
To block proliferation in the WoundMakerTM scratch assay for migration only, confluent
cells were treated with mitomycin C (10µg/mL) for 2 hours (Table 4.3).
Table 4.3 WoundMakerTM scratch assay experimental design
Drug Name

Drug Conc.

n of Drug Only

n of Drug + Mitomycin

Vehicle H2O

Volume of 10

6

11/12

10 µM

6

11/12

1 µM

5/6

11/12

DZA

10 µM

6

12

5-Azacytidine

10 µM

5/6

11/12

Elvitegravir

10 µM

5/6

11/12

Raltegravir

100 µM

6

11/12

Azidothymidine

10 µM

6

11/12

µl/ml
Vehicle DMSO
DZNEP

4.2.5 Transformation Assay
To study the in vitro anti-tumorigenesis effect of integrase and reverse
transcriptase inhibitors and the tumorigenesis potential of dysregulated epigenome
induce TE expression through SAM cycle inhibitors and DNA methyltransferase
inhibition we utilized transformation assays. Transformation assays require cell growth
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in an anchorage independent way. Non-transformed cells require adequate and
appropriate cell-matrix interactions, otherwise the undergo anoikis [27]. Anchorage
independent growth is a hallmark of transformation and is a stringent in vitro assay for
detecting nonmalignant to malignant transformation. All transformation assays were
performed according to a previously established protocol [28]. Briefly, the protocol
requires three layers of cell culture media and agarose in a 6 well cell culture plate. The
bottom layer is 2ml of 0.6% 2-hydroxyethyl agarose solution (Sigma, A4018) in media.
The middle layer is a cell-containing layer with 0.3% 2-hydroxethyl agarose solution in
media. The last layer is a feeder layer of 0.3% 2-hydroxyethyl agarose solution in media
to provide extended access to nutrients for cells. In treatment wells, the appropriate drug
dose is added to the cell-containing layer and feeder layer and is further explained below.
Feeder layers are added once a week. It is recommended that images be taken between
one and two weeks of growth.
Here we plated 2 x 104 cells per well in four 6-well plates for each cell line, MCF10A
and MCF10DCIS, and treated with respective drug in concentrations (Table 4.4).
Table 4.4 Transformation assay experimental design
Drug Name
Vehicle H2O

Drug Concentration n of MCF10A

n of MCF10DCIS

Volume of 10 µl/ml

NA

2

10 µM

2

2

1 µM

2

4

10 µM

3

3

Raltegravir

100 µM

NA

3

Elvitegravir

10 µM

3

4

Vehicle DMSO
DZNEP
DZA
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After 10 days a grid template was generated, images were taken with a 10mm lens
microscope camera at the west, north, east, south, and middle of each well. Colonies that
had a diameter of 50 µm or more were counted using ImageJ software.

4.3 Results
4.3.1 Cell Viability & Density Dose-Response Curves
A dose-response curve on viability and density was conducted for each drug to
determine the minimal effective dose in our cell culture assays using viability and density
assays. SAM cycle inhibitors DZA and DZNEP doses chosen were 10 µM and 1 µM,
respectively. At the 10 µM dose DZA had no change in cell viability compared to control
in both MCF10A and MCF10DCIS cell lines (Figure 4.2A & C). However, at 10 µM, DZA
in MCF10A cell line had increased cell density when compared to control (Figure 4.2B).
At the 1 µM dose DZNEP had a slight decrease in cell viability for both cell lines, when
compared to control, and a deficit in both cell lines for cell density (Figure 4.2). The
DNMT inhibitor AZA dose chosen was 10 µM. Little to no difference was detected for 1
µM of AZA treatment when compared to control (Figure 4.3). In contrast, 100 µM
treatment with AZA resulted in large deficits in cell density and a large decrease in cell
viability (Figure 4.3 A & C). 10 µM treatment with AZA resulted in no change of viability
with MCF10A and a slight decrease in viability in MCF10DCIS when compared to control
(Figure 4.3A & C). However, both cell lines experienced a deficit in density (Figure 4.3B
& D). Integrase inhibitors ELV and RAL doses chosen were 10 µM and 100 µM
respectively. ELV at 1 µM showed no real difference in cell viability and highly variable
results for density for both cell lines. At the 100 µM dose of ELV MCF10DCIS cells had a
decrease in cell viability and both MCF10A and MCF10DCIS had large deficits in cell
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density when compared to vehicle (Figure 4.4). Overall, RAL had little change in viability
and density when compared to control regardless of dose. Reverse transcriptase inhibitor
AZT dose chosen was 10 µM. There was little effect on cell viability when compared to
control for both MCF10A and MCF10DCIS cells line regardless of the treatment dose
(Figure 4.5). Cell density had varying results for treatment doses. At 1 µM MCF10DCIS
cells had a much greater density when compared to control (Figure 4.5D). Conversely, at
100 µM MCF10DCIS cells experience slight decrease in cell density (Figure 4.5D).
MCF10A cells had a slight increase in density at 1 µM and a slight decrease in cell density
at 100 µM (Figure 4.5B).

A

B

C

D

Figure 4.2 Initial Dose-Response Curve for SAM Cycle Inhibitors. A. MCF10A cell viability for DZA and
DZNEP doses. B. MCF10A cell density for DZA and DZNEP doses. C. MCF10DCIS cell viability for DZA and
DZNEP doses. D. MCF10DCIS cell density for DZA and DZNEP doses. Red star indicates doses chosen for
future studies, not an indicator of significance. (unpublished)
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A

B

C

D

Figure 4.3 Initial Dose-Response Curve for DNA Methyltransferase Inhibitor. A. MCF10A cell
viability for AZA doses. B. MCF10A cell density for AZA doses. C. MCF10DCIS cell viability for AZA
doses. D. MCF10DCIS cell density for AZA doses. Red star indicates doses chosen for future studies,
not an indicator of significance. (unpublished)

Figure 4.4 Initial Dose-Response Curve for Reverse Transcriptase Inhibitor. A. MCF10A cell
viability for AZT doses. B. MCF10A cell density for AZT doses. C. MCF10DCIS cell viability for
AZT doses. D. MCF10DCIS cell density for AZT doses. Red star indicates doses chosen for
future studies, not an indicator of significance. (unpublished)
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Figure 4.5 Initial Dose-Response Curve for Integrase Inhibitors. A. MCF10A cell viability for ELV and
RAL doses. B. MCF10A cell density for ELV and RAL doses. C. MCF10DCIS cell viability for ELV and
RAL doses. D. MCF10DCIS cell density for ELV and RAL doses. Red star indicates doses chosen for
future studies, not an indicator of significance. (unpublished)

4.3.2Scratch Assay
4.3.2a Pilot Study
To measure migration and growth during treatments to induce TE expression or
reduce TE activity scratch assays were performed. No significant results were found for
any of the treatments in either cell line until the 24-hour time point. At 24 hr post-stratch,
AZA and DZNEP had significantly less wound healed when compared to their vehicle
controls in MCF10A cell line. Nonsignificant increases of wound healing were seen in
MCF10DCIS cell lines for AZT, ELV, DZA, and AZA.
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Figure 4.6 Pilot Study of Wound Assay for MCF10A cell line. A. SAM cycle inhibitors DZA and DZNEP.
B. DNMTi AZA C. Integrase inhibitor ELV. D. Reverse transcriptase inhibitor AZT. (unpublished)

Figure 4.7 Pilot Study of Wound Assay for MCF10DCIS cell line. A. SAM cycle inhibitors DZA and
DZNEP. B. DNMTi AZA C. Integrase inhibitor ELV. D. Reverse transcriptase inhibitor AZT. (unpublished)
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4.3.2b WoundMakerTM
To confirm and extend pilot study results, we performed WoundMakerTM scratch
assays with drug treatment only. For MCF10A cells at 6hrs after the wound was generated
and treatment was applied only AZA had significant results when compared to control
with a decrease in the amount of wound healed (Figure 4.8B). AZA continued to have
significantly less amount of wound healed compared to vehicle control at each time point.
DZNEP also had significantly less wound healed when compared to vehicle control for all
time points except 6hrs (Figure 4.8A & B). ELV and DZA had significantly less wound
healed at 12 hours when compared to control (Figure 4.8A & C). For MCF10DCIS cell line
no significant difference was determined for any drug treatment at 6-hour timepoint. At
all other timepoints only AZA had significantly less wound healed when compared to
control (Figure 4.9B).
To determine migration only effects we performed WoundMakerTM scratch assay
with drug treatment + mitomycin treatment. In MCF10A cells, AZA had significantly less
migration at each timepoint when compared to vehicle control (Figure 4.10B). AZT had
nonsignificant increases in migration for the 6-hour and 12-hour timepoint (Figure
4.10E). In MCF10DCIS cells, again only AZA had significantly less migration when
compared to control at each timepoint (Figure 4.11B). Starting from 12 hours through 18
hours, RAL had significantly less migration when compared to control (Figure 4.11D).

125

TM

Figure 4.8 WoundMaker Scratch Assay for MCF10A cell line. A. SAM cycle inhibitors DZA
and DZNEP. B. DNMTi AZA C. Integrase inhibitor ELV. D. Integrase inhibitor RAL. E. Reverse
transcriptase inhibitor AZT. (unpublished)
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Figure 4.9 WoundMaker Scratch Assay for MCF10DCIS cell line. A. SAM cycle inhibitors
DZA and DZNEP. B. DNMTi AZA C. Integrase inhibitor ELV. D. Integrase inhibitor RAL. E.
Reverse transcriptase inhibitor AZT. (unpublished)
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Figure 4.10 WoundMaker Scratch Assay Migration Only for MCF10A Cell Line. A. SAM
cycle inhibitors DZA and DZNEP. B. DNMTi AZA C. Integrase inhibitor ELV. D. Integrase inhibitor
RAL. E. Reverse transcriptase inhibitor AZT. (unpublished)
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Figure 4.11 WoundMaker Scratch Assay Migration Only for MCF10DCIS Cell Line. A. SAM
cycle inhibitors DZA and DZNEP. B. DNMTi AZA C. Integrase inhibitor ELV. D. Integrase inhibitor
RAL. E. Reverse transcriptase inhibitor AZT. (unpublished)
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4.3.5 Transformation Assay
To determine anchorage-independent growth during treatments to induce TE
expression or reduce TE activity, transformation assays were performed. No significant
differences were found for any of the treatments when compared to control for MCF10A
cells (Figure 4.12). In MCF10DCIS cells, DZNEP had significantly fewer colonies with a
diameter of 50 µm or more when compared to control (Figure 4.13).

Figure 4.12 Transformation Assay for MCF10A Cell Line. A. SAM cycle inhibitors DZA and
DZNEP. B. Integrase inhibitor ELV. (unpublished)

Figure 4.13 Transformation Assay for MCF10DCIS Cell Line. A. SAM cycle inhibitors DZA and
DZNEP. B. Integrase inhibitor ELV. (unpublished)
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Table 4.5 Results Summary for MCF10A. Outcomes are based on treatment
compared to vehicle controls. ND no significant difference, NA not available, ↑ increased
percent of wound healed, ↓ decrease percent of wound healed.
Treatment Wound Healing
(Pilot)

Wound Healing

Wound Healing

(WoundMaker®)

(WoundMaker® +

Transformation

Mitomycin C)

DZA

ND

12hr↓

ND

ND

DZNEP

24hr↓

≥12hr↓

ND

ND

AZA

24hr↓

↓

↓

NA

ELV

ND

12hr↓

ND

ND

RAL

NA

ND

ND

NA

AZT

ND

ND

ND

NA
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Table 4.6 Results Summary for MCF10DCIS. Outcomes are based on
treatment compared to vehicle controls. ND no significant difference, NA not available,
↑ increased percent of wound healed, ↓ decrease percent of wound healed.
Treatment Wound Healing
(Pilot)

Wound Healing

Wound Healing

(WoundMaker®)

(WoundMaker® +

Transformation

Mitomycin C)

DZA

ND

ND

ND

ND

DZNEP

ND

ND

ND

ND

AZA

ND

≥12hr↓

↓

NA

ELV

ND

ND

ND

ND

RAL

NA

ND

12hr, 18hr ↓

ND

AZT

ND

ND

ND

NA

4.4 Discussion
These studies tested the role of retrotransposons in breast cancer progression
using pharmacological approaches and classic invasive and metastasis analysis assays.
Counter to our expected outcomes for DNMTi AZA, the drug consistently caused
significantly more cell death and decreased invasiveness when compared to control.
Additionally, SAM cycle inhibitor DZNEP consistently had significantly less migration in
MCF10A cells and less anchorage independent growth in MCF10DCIS cells. While
initially unexpected, these data corroborate recently published research. In 2015, Hurst
and Magiorkinis speculated that endogenous retroviruses activate the innate immune
response [29]. Later studies confirmed this and further determined the inhibition of DNA
methylation induced an interferon response due to endogenous retroviral expression
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[30]. I believe future studies with smaller doses of our DNA methylation disruptors may
further determine roles of retrotransposon expression in breast cancer progression by
allowing an increase in retrotransposon expression below the threshold necessary to
induce the innate immune response.
The nonsignificant increase in migration for MCF10A cells, when treated with the
reverse transcriptase AZT, is worth further exploration as it may suggest alternative
activities of RNA transcripts for retrotransposons. Conversely, the integrase inhibitor
RAL’s anti-migratory results may suggest a decrease in genomic destabilization prevents
metastatic progression. A decrease in genomic instability upon inhibition would support
the classic transposon activity in cancer model. Additional soft agar assay experiments
should be performed to further address trends not significant.
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Chapter Five:
Perspectives

5.1 Pipeline for the Common Clinical RNA-Seq Dataset
With the introduction and advancement of next-generation sequencing, biologists
and clinicians have made an enormous amount of discoveries in a short amount time
when compared to classic sequencing approaches. These next-generation sequencing
tools produce massive amounts of data and require special attention to their analysis
because of the potential effects of biological sample preparation, method of sequencing,
and questions of interest. An ideal translational experiment would involve fresh, or
freshly frozen, tissue samples micro-dissected from non-target tissues, immediately
prepped and sequenced. However, circumstances for clinicians and many biologists
working with specimens from human patients must rely on preservation methods, such
as, formalin fixed paraffin embedded (FFPE) tissue. These methods of preservation have
been known to increase nucleotide degradation [1-3].
Presented in this thesis, the analysis and comparison of common bioinformatics
tools study proved successful in the generation of a pipeline that is well-suited for lowquality, short nucleotide sequence reads data. As described in Chapter 2, this study
started by examining two common alignment tools, HISAT2 and STAR, to analyze RNASeq datasets derived from FFPE tissue samples. We further developed the pipeline by
comparing the two most common and robust differential expression analysis tools, edgeR
and DESeq2. We were able to discover that the version of HISAT2 used in the comparison
135

had significantly less reads mapped to the human genome. Furthermore, the reads
aligned by HISAT2, were assigned to pseudogene loci instead of genes, which may
indicate compromised alignment fidelity in preserved specimens that degrade
nucleotides. During the comparison of the differential expression tools, DESeq2 and
edgeR programs yielded similar results although it appears that edgeR’s estimateDisp
function had increased FDR correction for datasets with 12 or more replicates.
Many clinical and experimental laboratories often have their RNA-Seq samples
brought to a core or commercial analytics company for processing and analysis without
knowing the pipeline utilized on their data. Equivalently, many bioinformaticians process
RNA-seq read output without knowledge or understanding of the experimental
preparations executed at the clinician’s or experimentalist’s laboratory that can bias
sequencing output. Our study provides evidence that no single bioinformatics tool is
appropriate to apply to all experiments. Furthermore, parameters setting contribute to
outcomes for both mapping to a reference genome and measuring differential expression.
The studies support for STAR aligner to obtain the most robust, accurate alignment for
RNA-Seq data generated from FFPE samples. Furthermore, we recommend either
DESeq2 or edgeR if estimateDisp function is applied for studies with 12 or more replicates
and edgeR without estimateDisp function applied for studies with less than 12 replicates.

5.2 Novel In Silico Method for the Discovery of TE Expression in Breast
Cancer Progression
For decades it has been widely accepted that early pre-malignant breast cancer is
a precursor to the invasive form. Yet, there is little knowledge as to distinguish the cohort
of patients diagnosed with pre-malignant breast cancer that never progress to the invasive
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form. Few advances have been made in the evolutionary bottleneck theory of “one gene
mutation at a time” until a selected clone escapes the basement membrane. As previously
mentioned, a recent study using advanced single cell spatially resolved next-generation
sequencing provided evidence that clonal selection occurs before tumor cells escape the
basement membrane, subclones are derived from the same or a similar parent population,
and multiclonal migration occurs. Early heterogeneity and multiclonal escape suggest
there could be additional factors involved in basement membrane escape.
After optimizing the bioinformatics pipeline tools, breast cancer progression RNASeq data were analyzed to determine the TE expression signature. This analysis revealed
that the LTR retrotransposons family, ERV expression was the most differentially
expressed TE at each stage of breast cancer when compared to normal. Additionally, DCIS
had the highest percentage of TEs differential expressed at ERV genomic regions
compared to the percent of DE ERVs in other stages.
Interestingly, when gene coding regions were analyzed for differential expression
and gene enrichment analysis with gene ontology terms the outputs revealed interferon
responses and antiviral activity starting at the DCIS stage. These data corroborate the
higher percentage of ERVs differentially expressed in DCIS. Furthermore, our transcript
analysis revealed progressive diversification of GO terms associated with metastasis from
atypia to IDC. This in silico study provides a foundation of evidence for TE, specifically
ERV, involvement in breast cancer progression from pre-malignant to malignancy.
However, replicate findings in silico analysis of RNA-seq data from other independently
collected specimens and experimental evidence are needed to substantiate our
discoveries.
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5.3 Regulating Retrotransposon Expression and Activity Effects on MCF10A
and MCFDCIS Cell Line Models
This study provides convincing introductory data for a role of retrotransposons in
breast cancer progression. Retrotransposition induced genetic instability is a hallmark of
advanced cancers [4]. HERV-K particles have been discovered in the plasma of patients
diagnosed with invasive breast cancer. An important regulator and repressor of
retrotransposon expression is DNA methylation and other epigenetic mechanisms.
Previous microarray studies postulate epigenetic dysregulation at retrotransposon loci in
cancerous tissue when compared to adjacent normal tissue. This study examines the role
of retrotransposons in the establishment of metastatic phenotypes of breast cancer using
MCF10A and MCF10DCIS cell lines as a model of progression.
Using a pharmacological approach, the contribution of retrotransposon expression
to metastatic phenotypes was examined, such as increased migration and anchorage
independent growth, by treating with DNA methylation disruptors and retroviral reverse
transcriptase and integrase inhibitors. Our results indicate DNA methylation inhibitor 5Azacytidine (AZA) consistently significantly decreased and retarded cell migration and
growth. These results are not caused by toxicity because cell viability assays showed
MCF10DCIS cells with decreased viability only at doses higher than used for these
experiments. While these findings were unexpected; they corroborate a few recent
studies. In 2015, a paper reported the possibility that ERVs contributes to an increase in
the innate immune response. That same year it was found that AZA induced an interferon
response in cancer by depressing ERV expression. These studies have provided data
supporting the possibility of using AZA, and other epigenetic deregulators, as a
therapeutic option. Within the last year several studies have started testing known
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epigenetic deregulators to induce ERV expression beyond a threshold of tolerance, for a
“viral mimicry”, and initiate an immunotherapy response [5-7]. It’s important to note that
these studies are providing evidence of an ERV expression threshold to induce immune
response. These do not discount or discredit the diverse roles TEs play in oncogenesis as
determined from prior studies [8-16].

The significant mitigation of migration on

MCF10DCIS cells when treated with an integrase inhibitor RAL corroborates the
contribution of insertional mutagenesis to advanced cancers. However, further
pharmacokinetic studies must be performed to determine ERV activity and ensure the
significant decrease isn’t due to cellular toxicity. Many of the drugs at the doses chosen
did not produce significant differences. Additional dose-dependent response curve
studies should be done to explore effective concentrations.
A major limitation to this study is in the time of exposure during the wound healing
assays. Drug induced expression of transposable element insertional mutagenesis may
require weeks of treatment exposure to ensure oncogenic clonal selection occurs.
Likewise, pretreatment may also provide insight into how TEs drive transformation,
whether through classical TE mutagenesis or alternative TE activities, like alternative
promoter exaptation driving oncogenes. To overcome this limitation further experiments
with pretreatments for 1 to 2 weeks in drug may be performed. Additional limitations
include the current spectrum of doses tested, the number of transformation assays
completed, the lack of RNA-seq data for cell line models concordance with clinical RNAseq data, and the lack of direct experimental evidence to suggest transposable activity is
driving transformation.
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5.4 Future Directions
5.4.1 Transposable Element Expression in Breast Cancer Cell Lines
The use of MCF10A cell line and its derivations of cancer cell lines as a model for
breast cancer progression has been extensively studied [17-20]. However, little is known
as to its concordance of transposable element expression during MCF10A transformation
and derived cancer lines with clinical samples of breast cancer progression. Therefore, it
is imperative to determine the TE expression profile of the specific cell lines we use as
models of oncogenic phenotypes during TE dysregulation and TE activity inhibition.

5.4.2 Activity of Transposable Elements
The use of pharmaceuticals within a dose range known to induce TE expression or
inhibit TE activity to measure metastatic potential is necessary. However, it is imperative
these studies be done in conjunction with studies that can measure activity of
transposable elements. One such approach is the reverse transcriptase activity assay.
Briefly, purified bacteriophage MS2 RNA are incubated with cell lysate aliquots. Mixtures
are exposed to PCR amplification using MS2-specific primer pairs to determine if MS2
cDNA sequences were synthesized. The presence of amplified MS2 cDNA is a measure of
reverse transcriptase activity. The assay is roughly based on the protocol established by
Voisset et al., 2001 [21]. Versions of the assay have previously described endogenous
reverse transcriptase activity in preimplantation embryos and cancer [22, 23].

5.4.3 Patient-Derived Xenograft Models
Patient-derived tumor xenograft (PDX) mouse models offer a unique translational
prospect for breast cancer progression research. These models seem to be quite similar to
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their donor, retaining important tumor histomorphology, imaging and gene expression
characteristics of the donor [24-26]. Furthermore, they have been used to study predictive
clinical outcomes with regards to drug efficacy, biomarker analysis, and patient outcomes,
reviewed here [27], with high concordance between patients and their PDX models.
However, there is a lack of published studies with PDX models recapitulating breast
cancer progression from non-obligate in situ carcinomas to metastasis. Not only would
these studies provide valuable insight into why only 1/3 of patients progress into invasive
breast cancer they may also indicate biomarkers or factors for invasiveness. Furthermore,
currently there are no studies revealing the transposable element or non-coding RNA
expression profile for breast cancer PDX models.

5.5 Final Thoughts
The idea that TEs were fundamental and continue to contribute to the evolution of
regulating gene networks started with the pioneering work of Dr. Barbara McClintock.
The selfish replicative nature of TEs has predisposed them to the co-option of host gene
regulation. However, this co-option of TEs is widely seen as a double-edged sword. As
described in Chapter 3, there is a large body of evidence for the diversity of domesticated
TE mechanisms employed by whole organism, tissue-specific, and cellular systems.
Contrarily, strong evidence linking aberrant TE activity to disease states, such as, cancer,
ageing, neurological disorders, and autoimmunity is increasing. The double-edge nature
of parasitic elements becoming integral components of many host functions presses for
more granular experimental evidence of TE activity at the individual element level. We
are in the gene-targeted therapy revolution. Current technologies, such as CRISPR-Cas
systems, are becoming increasingly more accurate at genetic and RNA manipulation. As
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technologies advance toward functionally testing non-coding and repeat regions of the
genome, it will provide greater, much needed, insight into the roles of TEs in disease
states.
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